Document:

EX-10.1

 Exhibit 10.1 

Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit because it is both not material and would be
competitively harmful if publicly disclosed. 
 CLINICAL SUPPLY AGREEMENT 

DRUG PRODUCT 
 THIS CLINICAL SUPPLY
AGREEMENT (this “Agreement”) is entered into and effective this 4th day of October 2019 (“Effective Date”) by and between Catalent Indiana, LLC, a Delaware limited liability company with offices 1300 South
Patterson Drive, Bloomington, IN 47403 (“Catalent”) and Catalyst Biosciences, Inc. (“Client”), a Delaware corporation with offices at 611 Gateway Boulevard, Suite 710, South San Francisco, CA 94080. In this
Agreement, Catalent and Client each may be referred to individually as a “Party” and together as “Parties.” 

RECITALS 
 WHEREAS, Catalent is a leading
provider of advanced technologies, and development, manufacturing and packaging services, for pharmaceutical, biotechnology and consumer healthcare companies; 

WHEREAS, Client develops pharmaceutical products; and 
 WHEREAS,
Client desires to have Catalent provide the Services (as defined below) set forth in this Agreement and any Project Plan, and Catalent desires to provide such Services to Client through certain of its locations (see definition of Facility below),
all pursuant to the terms and conditions in this Agreement. 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein, the
Parties agree as follows: 
 AGREEMENT 
  

	1.	 Definitions. For purposes of this Agreement, the following terms will have the meanings set forth
below: 

  

	 	1.1	 “Affiliate” with respect to Client, means Catalyst Biosciences, Inc. and any
corporation, firm, partnership or other entity controlled by it; and with respect to Catalent, means Catalent, Inc. and any corporation, firm, partnership or other entity controlled by it. For the purposes of this definition, “control”
means the ownership of at least 50% of the voting share capital of an entity or any other comparable equity or ownership interest. 

  

	 	1.2	 “ANDA” means an Abbreviated New Drug Application. 

  

			
	CONFIDENTIAL INFORMATION	  	Page 1 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	1.3	 “Applicable Laws” with respect to Client, means all laws, ordinances, rules and
regulations, as amended from time to time, of each jurisdiction in which Bulk Drug Substance or Product is produced, marketed, distributed, used or sold by or on behalf of Client; and with respect to Catalent, means all laws, ordinances, rules and
regulations, as amended from time to time, of the jurisdiction in which Catalent performs Services; provided that CGMP shall not constitute Applicable Laws except to the extent expressly stated in the applicable Project Plan. 

 

	 	1.4	 “Batch” means a specific quantity of a Product comprising a number of Units mutually
agreed upon between Client and Catalent, and that: (a) is intended to have uniform character and quality within specified limits; and (b) is Produced according to a single manufacturing order during the same cycle of Production.

  

	 	1.5	 “Batch Record Package” has the meaning stated in the Quality Agreement.

  

	 	1.6	 “BLA” means a Biologic Licensing Application. 

 

	 	1.7	 “Bulk Drug Substance” means the bulk form of the active ingredient identified in the
Project Plan that is used in the Production of Product. 

  

	 	1.8	 “Certificate of Analysis” means a document listing all test results for a Product, Raw
Material, or Component compared to the respective Specifications. 

  

	 	1.9	 “CGMP” means those current practices, as amended from time to time, related to the
manufacture of biopharmaceuticals and pharmaceuticals as set forth in the FDCA and such standards of good manufacturing practice as are required by the FDA or other Regulatory Authorities (as defined herein), as agreed in the Project Plan and as may
be set forth in the United States Code of Federal Regulations (Title 21, Parts 210-211). 

  

	 	1.10	 “Client Confidential Information” means: (a) all Confidential Information owned or
controlled by Client that is disclosed to Catalent under this Agreement; and (b) all Information concerning Product Specifications, Client Intellectual Property Rights, Client Materials, Component Specifications, Master Batch Records, and
Product Inventions. 

  

	 	1.11	 “Client Intellectual Property Rights” means: (a) all patent and other intellectual
property rights owned or controlled by Client as of the Effective Date; and (b) all patent and other intellectual property rights developed, authored, conceived, or reduced to practice by or on behalf of Client not in connection with this
Agreement. 

  

			
	CONFIDENTIAL INFORMATION	  	Page 2 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	1.12	 “Client Materials” means the materials for use in the Production supplied by Client to
Catalent, or that Catalent does not routinely stock and specially procures on behalf of Client as outlined in the executed Project Plan. 

  

	 	1.13	 “Client Trademarks” means the proprietary mark(s) for Product owned or controlled by
Client as identified in a Project Plan. 

  

	 	1.14	 “Component Specifications” means the Specifications for the Components set forth in the
Project Plan, including the testing (if any) to be performed for the Components, as set forth in the Project Plan. 

  

	 	1.15	 “Components” means all primary product-contact components (such as vials, plungers,
stoppers and syringes) or product-delivery devices (such as secondary devices or injectors) of the type required for Production. All Components will be specified and listed in the Project Plan and may be identified as either Components supplied by
Client (“Client-Supplied Components”) and/or Components supplied by Catalent (“Catalent-Supplied Components”). 

  

	 	1.16	 “Confidential Information” shall mean all information and materials acquired from the
other Party or its Affiliates, employees, subcontractors, suppliers, agents, distributors, licensees or customers in connection with this Agreement, as well as all other information and materials included in the Client Confidential Information.

  

	 	1.17	 “Catalent Intellectual Property Rights” means: (a) all patent and any other
intellectual property rights owned or controlled by Catalent as of the Effective Date; and (b) those intellectual property rights that are developed, authored, conceived, or reduced to practice by or on behalf of Catalent not in connection with
this Agreement. 

  

	 	1.18	 “Catalent Project Product Code” means the identifying alphanumeric code established by
Catalent to identify the Product as set forth in the Project Plan. 

  

	 	1.19	 “Claim” means any claim, demand, suit, action, or proceeding. 

 

	 	1.20	 “Damages” means any and all costs, losses, liabilities, fines, penalties, costs and
expenses, court costs, and fees and disbursements of counsel, consultants and expert witnesses incurred by a Party hereto (including interest which may be imposed in connection therewith). 

  

			
	CONFIDENTIAL INFORMATION	  	Page 3 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	1.21	 “Dedicated Equipment” means the equipment, if any, identified on a Project Plan as
“Dedicated Equipment” that is purchased or otherwise provided by Catalent or Client and exclusively dedicated to use by Catalent in the provision of the Services. 

 

	 	1.22	 “Development/Engineering Batch” shall have the meaning set forth in Section 3.3.

  

	 	1.23	 “EMA” means the European Medicines Agency and any successor agency having substantially
the same functions. 

  

	 	1.24	 “Facility” means the Catalent manufacturing facility located at 1300 South Patterson
Drive, Bloomington, Indiana 47403. 

  

	 	1.25	 “FDA” means the United States Food and Drug Administration and any successor agency or
entity that may be established hereafter. 

  

	 	1.26	 “FDCA” means the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 301 et seq.).

  

	 	1.27	 “Firm Order” means any of the following, each of which shall constitute a commitment by
Client to purchase Product: (i) a Project Plan duly executed by the Parties which contains a binding order for the Product; or (ii) an accepted and confirmed purchase order that is subject to the terms and conditions of this Agreement.

  

	 	1.28	 “Force Majeure” means causes beyond the reasonable control of a Party including,
without limitation, acts of God (including but not limited to earthquake, tornado or hurricane), laws, regulations or actions of any government or agency thereof, war, terrorism, civil commotion, damage to or destruction of production facilities or
materials, scientific or technical events, labor disturbances (whether or not any such labor disturbance is within the power of the affected Party to settle) and pandemic or epidemic events. 

 

	 	1.29	 “Indemnitee” has the meaning stated in Section 7.3 (“Procedure for
Indemnification”). 

  

	 	1.30	 “Indemnitor” has the meaning stated in Section 7.3 (“Procedure for
Indemnification”). 

  

	 	1.31	 “Initial Term” has the meaning stated in Section 10.1 (“Term”).

  

			
	CONFIDENTIAL INFORMATION	  	Page 4 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	1.32	 “Inventions” means all innovations, inventions, improvements, original works of
authorship, developments, concepts, know-how and/or trade secrets, whether or not patentable, resulting from the performance of the Services. 

 

	 	1.33	 “Master Batch Record” means, with respect to each Presentation of Product to be
Produced hereunder, a formal set of instructions for the Production of each Presentation of such Product. 

  

	 	1.34	 “NDA” means a New Drug Application. 

 

	 	1.35	 “Nonconforming Product” has the meaning stated in Section 4.1 (“Product
Conformity”). 

  

	 	1.36	 “Non-Defaulting Party” has the meaning stated
in Section 10.2 (“Termination for Breach”). 

  

	 	1.37	 “Party” or “Parties” has the meaning stated in the opening
paragraph. 

  

	 	1.38	 “Permitted Subcontractor” has the meaning stated in Section 12.12
(“Subcontracting”). 

  

	 	1.39	 “Person” means a natural person, a corporation, a partnership, a trust, a joint
venture, a limited liability company, any governmental authority or any other entity or organization. 

  

	 	1.40	 “Presentation” means the specific formula and Components used for a Product.

  

	 	1.41	 “Price” has the meaning stated in Section 5.1 (“Product Price”).

  

	 	1.42	 “Process” means the formulation, filling, inspecting, labeling, packaging and testing
of the Product using the Product Specifications in accordance with the Master Batch Record, including any improvements thereto from time to time made as a direct result of the Services during the Term of the Agreement. 

 

	 	1.43	 “Process Consumables” shall mean materials used as an aid in the Production of Product
that do not become part of the finished Product including but not limited to filters, tubing, Product contact disposables, containers, and bags. 

  

	 	1.44	 “Product Liability Claims” means, with respect to any Product, a Claim of a third party
that arises as a result of the use of such Product that results in personal injury or death. 

  

	 	1.45	 “Produce” or “Production” means the verb form of the term Process.

  

			
	CONFIDENTIAL INFORMATION	  	Page 5 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	1.46	 “Product” means the formulated Bulk Drug Substance in syringes, cartridges, and/or
vials packaged as specified in the applicable Project Plan(s). 

  

	 	1.47	 “Product Availability Date” means the date that Product is made available to Client or
its designated carrier in accordance with the Delivery Terms. 

  

	 	1.48	 “Product Invention” means any Invention that specifically relates to the Product
(including relating to the Components or to the composition or utility of the Bulk Drug Substance or the Product) and that is developed, conceived, or reduced to practice by or on behalf of Client or Catalent in the performance of the Services. For
the avoidance of doubt, a Product Invention shall include Inventions made by or on behalf of Catalent, by or on behalf of Client, or jointly by or on behalf of Catalent and Client. 

 

	 	1.49	 “Product Requirements” has the meaning stated in Section 4.1 (“Product
Conformity”). 

  

	 	1.50	 “Product Specifications” means, with respect to each Product, the Specifications for
the Product, and/or the stability program that are set forth in the Client-specific standard operating procedures and the Master Batch Records. The Product Specifications include all tests that Catalent is required to conduct or cause to be
conducted as specified in the Project Plan. The Product Specifications may be modified from time to time only by a written agreement signed by Client and Catalent. 

 

	 	1.51	 “Project Invention” means any Invention developed, conceived, or reduced to practice
during the Term in the course of, and as a direct result of, performing the Services, excluding Product Inventions. For the avoidance of doubt, a Project Invention shall include Inventions made solely by or on behalf of Catalent, by or on behalf of
Client or jointly by or behalf of Catalent and Client. 

  

	 	1.52	 “Project Plan” means all document(s) labeled “Project Plan” that refer to
this Agreement, and that are signed by authorized representatives of both Parties setting forth the proposed course of action for the Production of Product and/or performance of Services at a specified Facility. A Project Plan may include, without
limitation, a description of the Product, Components, Regulatory Authorities and the countries where such Product will be used or sold, Presentations, Bulk Drug Substance, pricing for Product(s) Produced and Services provided under this Agreement as
set forth in Section 3.5 (“Project Plan”), and any applicable reservation fee necessary to reserve a manufacturing suite for CGMP services. 

  

			
	CONFIDENTIAL INFORMATION	  	Page 6 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	1.53	 “Quality Agreement” means the Quality Agreement applicable to the Services being
performed by Catalent. 

  

	 	1.54	 “Quality Disposition” means disposition of Product by Catalent’s Quality Assurance
department following Catalent Quality review of executed Batch documentation. 

  

	 	1.55	 “Raw Materials” means the materials used in the Production of the Product that may
become part of the finished Product such as Bulk Drug Substance, excipients, media components, and buffer components. 

  

	 	1.56	 “Regulatory Approval” means all authorizations, approvals, licenses, and registrations
issued by or otherwise required from the appropriate Regulatory Authority necessary for the Production, distribution, use or commercial sale in a jurisdiction. 

 

	 	1.57	 “Regulatory Authority” means any national, state, provincial, or local or any foreign
or supranational government, governmental, regulatory or administrative authority, agency or commission of any court, tribunal or judicial or arbitral body. 

  

	 	1.58	 “Safety Data Sheet” or “SDS” is a document that contains information
on the potential hazards (health, fire, reactivity and environmental) and how to work safely with the chemical product. It also contains information on the use, storage, handling and emergency procedures related to the hazards of the material.

  

	 	1.59	 “Services” means all or any part of the activities, including the Production of
Product, development services, and/or regulatory services for Client, to be performed by Catalent (and any Permitted Subcontractor) pursuant to this Agreement as further described in the executed Project Plan. 

 

	 	1.60	 “Specification(s)” means the tests, analytical procedures, and appropriate acceptance
criteria that are numerical limits or ranges that establish a set of criteria to which a raw material, component, drug substance or drug product must conform to be acceptable for its intended use. 

 

	 	1.61	 “Term” has the meaning stated in Section 10.1 (“Term”).

  

	 	1.62	 “Testing Laboratories” means any third party instructed by Catalent to carry out tests
on the Bulk Drug Substance, and/or the Product. 

  

			
	CONFIDENTIAL INFORMATION	  	Page 7 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	1.63	 “Tests” means the tests to be carried out on the Product (or samples thereof)
immediately following pick-up of the Product (or samples thereof) by Client, as stated in the Project Plan. 

  

	 	1.64	 “Testing Standards and Procedures” means, with respect to each Product Produced
hereunder, the written standards and procedures for evaluating compliance with the applicable Product Specifications, as mutually agreed upon in writing by Client and Catalent and incorporated in the applicable Project Plan. 

 

	 	1.65	 “Unit” means an individually packaged dosage form of a Product, including by way of
example only, a vial or prefilled syringe, as specified in the applicable Project Plan. 

  

	 	1.66	 “United States” means the fifty (50) states, the District of Columbia and all of
the territories of the United States of America. 

  

	2.	 Sourcing of Materials and Components. 

 

	 	2.1.	 Client-Supplied Raw Materials and Components Delivery. Client, at Client’s sole expense,
shall deliver or cause to be delivered to the Facility: (a) a reasonably sufficient amount of Client-supplied Raw Materials, and Certificates of Analyses, for Production of the Product in accordance with the applicable Project Plan; and
(b) all Client-Supplied Components listed in the applicable Project Plan, all of which shall be delivered to Catalent at the Facility at least [***] days in advance of the date set forth in the applicable Project Plan for commencement of
Production of such Product. Except as may specifically be set forth in the Project Plan, on receipt of the Client-supplied Raw Materials and Client-Supplied Components as set forth above, Catalent’s sole obligation with respect to evaluation of
the Client-supplied Raw Materials and Client-Supplied Components shall be to conduct identification testing and to review the accompanying Certificate of Analysis to confirm that the Client-supplied Raw Materials and Client-Supplied Components (if
applicable) conform with the Product Specifications and Component Specifications, respectively. Catalent shall use [***] efforts to minimize loss of the Bulk Drug Substances at all times while in Catalent’s possession and control, including
during the course of Producing the Product, and to otherwise maximize the yield of the Product during Production. 

  

	 	2.2.	 Safety Data Sheet. Client shall provide to Catalent a Safety Data Sheet for all Client materials
(including, if applicable, Bulk Drug Substance) and for each Product. Catalent shall notify Client of any unusual adverse health or environmental occurrence relating to the Product, including but not limited to any claim or complaint by any Catalent
employee or third party that the 

  

			
	CONFIDENTIAL INFORMATION	  	Page 8 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	
operations of Catalent pursuant to this Agreement have resulted in any adverse health or safety effect on an employee or third party. Each Party agrees to advise the other Party immediately of
any safety or toxicity problems of which it becomes aware regarding the Product and/or the Client Materials. 

  

	 	2.3.	 License Grant. Subject to the terms and conditions of this Agreement, Client hereby grants to
Catalent a non-exclusive, non-sublicensable (except to Permitted Subcontractors), non-transferable license during the Term
(except as otherwise set out in this Section 2.3) under Client’s intellectual property rights in the Client Confidential Information, the Client Intellectual Property Rights, the Product Inventions, and the Client Materials solely for the
purpose of performing Catalent’s obligations under this Agreement. The foregoing license shall extend beyond termination of this Agreement solely as necessary to complete the Production of outstanding Firm Orders. 

 

	 	2.4.	 Catalent Obligations Relating to Client Materials. Catalent shall: 

 

	 	2.4.1	 at all times use [***] efforts to keep the Client Materials secure and safe from loss or damage;

  

	 	2.4.2	 at all times store and handle the Client Materials under qualified conditions in a secured storage
location in accordance with Client’s handling and storage instructions and CGMP; 

  

	 	2.4.3	 use the Client Materials solely for the purpose of performing the Services; and 

 

	 	2.4.4	 not transfer to a third party any part of the Client Materials or the Product, except to Permitted
Subcontractors as may be permitted in the Project Plan. 

  

	 	2.5.	 Ownership and Risk of Loss. Client shall own and continue to own all right, title and interest in
and to Client Materials. Client assumes any and all risk of loss, damage, theft or destruction of Client Materials and Product while the Client Materials and Product are in Catalent’s possession, on Catalent’s premises, or while between
Catalent Facilities; [***] that [***] hereby [***], and [***] be [***], for [***], or [***] of [***] and [***] from [***], all [***] to the [***] set forth in [***]. Upon termination or expiration of this Agreement, Client shall promptly notify
Catalent whether Client shall either: (a) reclaim possession of Client Materials and Product; or (b) request destruction of Client Materials and Product by Catalent, each at Client’s sole expense. If Client fails to provide Catalent
such notice within [***] days following expiration or termination of this Agreement, Catalent shall destroy Client Materials and Product at Client’s sole expense. Catalent shall invoice Client (and Client shall pay) for all costs incurred as a
result of the return or destruction of the Client Materials and Product. 

  

			
	CONFIDENTIAL INFORMATION	  	Page 9 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	2.6.	 Vendor and Supplier Audit and Certification. Catalent shall certify and audit all Product-related
vendors and suppliers of Catalent-Supplied Components, Raw Materials, and Process Consumables at its sole expense unless the responsibility for such certifications and audits is specifically assumed by Client under the Project Plan. Client shall
certify and audit all vendors and suppliers of Client-supplied Raw Materials and Client-Supplied Components unless the responsibility for such certification and audits is specifically assumed by Catalent under the Project Plan and Client shall pay
for such audits as set forth therein. 

  

	 	2.7.	 Client-Supplied Components. Client shall supply to Catalent, or cause to be shipped to Catalent, all
Client-Supplied Components at Client’s expense. 

  

	 	2.8.	 Catalent-Supplied Components. Catalent will use [***] efforts to purchase the Catalent-Supplied
Components in quantities sufficient to meet Client’s Firm Orders for Product, including additional quantities as necessary for efficient supply chain management practices. Client shall reimburse Catalent for the Catalent-Supplied Components as
set forth in the Project Plan. Stock materials will be invoiced upon consumption. Custom (or non-stock) materials purchased by Catalent for Client will be invoiced (and title shall transfer to Client) upon
receipt of such non-stock materials by Catalent. Such materials shall be deemed Client Materials upon transfer of title to Client. Generation of invoices and payment for Catalent-Supplied Components shall be
made in accordance with Section 5.3 (“Payment Terms”) of this Agreement. 

  

	3.	 Purchase and Supply of Product. 

 

	 	3.1.	 Agreement to Purchase and Supply. Pursuant to the terms and conditions of this Agreement and the
applicable Project Plan, Client shall purchase from Catalent, and Catalent shall perform the Services and/or Produce and deliver to Client, the Product. 

  

	 	3.2.	 Performance. Catalent shall diligently perform the Services and/or the Production as provided in
the applicable Project Plan, including by meeting the schedule and Producing the Product in accordance with the Product Specifications and quantities provided in the applicable Project Plan and the approved purchase orders (unless such schedules are
estimates, in which case Catalent will use [***] efforts to meet such schedules). Catalent shall Produce Product in accordance with CGMP, all Applicable Laws, and all requirements set forth by applicable Regulatory Authorities. Client acknowledges
that the 

  

			
	CONFIDENTIAL INFORMATION	  	Page 10 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	
Services to be performed pursuant to this Agreement and the Project Plan are developmental and that the Services may involve biological processes that are, by their nature, unpredictable, and
Catalent does not guarantee to Client the achievement of a successful outcome. It shall not be considered a breach by Catalent of this Agreement or the applicable Project Plan if an objective of the applicable Project Plan is not achieved as long as
Catalent has complied with its obligations set forth in this Agreement and in the applicable Project Plan. Notwithstanding Section 12.12, Catalent shall have the right to cause any of its Affiliates to perform any of its obligations pursuant to
this Agreement, and Client shall accept such performance as if it were performance by Catalent. Catalent shall be responsible for the acts and omissions of its Affiliates in connection with the performance of Catalent’s obligations under this
Agreement as if such act or omissions were performed by Catalent. 

  

	 	3.3.	 Development/Engineering Batch. Except as otherwise agreed by the Parties in writing, the [***] of
[***] by [***] shall be considered to be a “Development/Engineering Batch.” Additionally, the [***] of the [***] Produced following: (a) a material change in Product Specifications; or (b) a change in scale of the
manufacturing process to produce different quantities of Product shall be considered a Development/Engineering Batch. 

  

	 	3.4.	 Reproduction, Rework or Reprocessing. If, during the Production of any Batch of Product, any
reprocessing, rework, or reproduction is required in order to meet the Product Specifications, upon Client’s prior, written approval, Catalent shall conduct such reprocessing, rework, or reproduction in compliance with CGMPs and the BLA or NDA
(as applicable). Catalent will notify Client if any reprocessing, rework, reproduction, or change is not covered by CGMPs, the NDA, or BLA. Approved reprocessing, rework, or reproduction shall be billed separately to Client at mutually agreed upon,
commercially reasonable fees. 

  

	 	3.5.	 Project Plan. 

 

	 	3.5.1	 Project Plan. For each Product to be Produced by Catalent hereunder, the Parties shall execute
one or more written Project Plan(s) prior to commencement of any work or commitment by Catalent to purchase or supply any Services, Raw Materials or equipment, or reservation of production capacity or schedule slots. Catalent, or any of its
Affiliates, may enter into one or more Project Plan(s) with Client under this Agreement, and such Affiliate shall assume the rights and obligations of Catalent under this Agreement for purposes of any applicable Project Plan(s). Each Project Plan

  

			
	CONFIDENTIAL INFORMATION	  	Page 11 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	
shall describe the Production with respect to the applicable Product, the budget for such Project Plan, and certain other relevant terms and conditions for performance of the Production by
Catalent under this Agreement. In no event shall Catalent be required to schedule the Production of any Product until a Project Plan for such Product has been approved in writing by both Catalent and Client. Each agreed-upon Project Plan shall be
incorporated herein by reference and shall constitute a Firm Order. 

  

	 	3.5.2	 Modification and Project Plan Scope Changes. From time to time, but no less often than once per
month, the Parties will meet to review and, if necessary, update, by mutual agreement, each Project Plan. In the event that the Parties agree to update, modify or expand the scope of a Project Plan, or to formally approve the accumulated minor
project changes as set forth in the following Section, such amended Project Plan will become part of this Agreement in the manner stated in Section 3.5.1 (“Project Plan”) upon execution of that Project Plan by authorized
representatives of both Parties. No Project Plan may be modified, amended, or supplemented except by written agreement by the Parties. 

  

	 	3.5.3	 Minor Project Changes. The Catalent project manager shall maintain an ongoing log which tracks all
Client-requested or Catalent-requested minor changes to the activities and items contained in an executed Project Plan. All such minor changes must be approved in writing by the Client project manager and the Catalent project manager in order to
take effect. Catalent is authorized to implement (and charge Client for) all such approved minor changes, provided that if the estimated total value of such tracked changes exceeds [***] percent of the total price of the Project Plan, then a formal
Project Plan amendment must be prepared, agreed to, and executed as set forth in the previous Section. 

  

	 	3.6.	 No Amendment of Agreement. In the event that the terms of any Project Plan are inconsistent with
the terms of this Agreement, this Agreement shall control, unless otherwise explicitly agreed to in writing by the Parties. No Project Plan shall be deemed to amend this Agreement. Upon execution of any Project Plan, such plan shall be deemed to be
incorporated herein and by reference and made a part of this Agreement. 

  

			
	CONFIDENTIAL INFORMATION	  	Page 12 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	3.7.	 Effect of Failure to Execute Plans or Addendum. No Party will have any obligations with respect to a
particular Product until the Parties execute a Project Plan with respect to that particular Product. 

  

	 	3.8.	 Cancellation of Firm Order. Client may cancel or delay any Firm Order [***] by providing [***] of
the [***]; provided, however, that if [***] than [***] in [***] by [***], then [***]: (i) [***] for the [***] that [***] and has [***] or [***], if such [***] by [***] for the [***] and such [***] used [***]; and (ii) [***] and [***] by [***]
up to the time of [***] of [***]. To the extent that such cancellation or delay causes Client to miss a Batch production slot (“Missed Slot”), Catalent will use [***] efforts to: (a) move the batch of another Catalent customer
into such Missed Slot (subject to such customer’s consent and provided that such movement does not cause a subsequent empty slot in Catalent’s schedule within the following [***] calendar weeks); and (b) mitigate and otherwise
minimize costs relating to such Missed Slot (including cancelling all revocable fees and expenses), and any fees due to Catalent under this Section 3.8 will be reduced by the sum of the fees paid for by such other customer for such batch.

  

	 	3.9.	 Storage. 

 

	 	3.9.1	 Client-Supplied Component Storage. Catalent shall store all Client-Supplied Components for the
remainder of the calendar month in which Client-Supplied Components arrive at Catalent and for the [***] following calendar months, without charge. On the first day of each calendar month thereafter that the Client-Supplied Components are stored by
Catalent, Catalent shall invoice Client (and Client shall pay) for a full month of storage for such Client-Supplied Components. In no event shall Catalent be required to store any such Client-Supplied Components for more than ninety (90) days
without Catalent’s consent. 

  

	 	3.9.2	 Product Storage. During the Term, Catalent shall store Products using the Dedicated Equipment
after Catalent Quality Disposition for the Products takes place. If the Dedicated Equipment fails, is full, or is not available, Catalent may make other arrangements for storage (as described in, and subject to, Section 3.9.3).

  

			
	CONFIDENTIAL INFORMATION	  	Page 13 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	3.9.3	 Storage Pricing and Off-Site Storage. Catalent shall be
permitted to store Product and Client-Supplied Components in mutually acceptable off-site, third party storage facilities. The applicable Project Plan may include pricing for storage, and Client agrees to pay
for such storage for as long as the Client-Supplied Components remain at Catalent’s Facility or at a mutually acceptable off-site storage facility. Catalent shall be responsible for any such off-site storage. If the Project Plan does not set forth storage charges, storage shall be charged at Catalent’s generally applicable storage rates that are in effect at the time the storage occurs.

  

	 	3.9.4	 Default. In the event of a default by Client with respect to payment of storage fees for the
Client-Supplied Components that is not cured within [***] days of Catalent’s written notice to Client of such default, then Catalent may at its sole discretion dispose of such items and invoice Client for all reasonable disposal costs incurred
by Catalent and set-off any and all amounts due to Catalent from Client under this Agreement against any credits Client may hold with Catalent under this Agreement. 

 

	 	3.10.	 Changes in Manufacturing. 

 

	 	3.10.1	 Changes to Master Batch Records. Catalent agrees to inform Client within [***] days of the result
of any regulatory development that reasonably may materially affect the Production of the Product. Catalent shall notify Client of and require timely written approval from Client for changes to Master Batch Records and Product
Specifications prior to the Production of subsequent Batches of Product. Within [***] days of learning from Catalent of such regulatory development, Client may either: (i) terminate this Agreement upon written notice to Catalent (in which
case Client shall be liable for any unfilled Firm Orders as of the termination date in accordance with Section 3.8); or (ii) approve of the changes. Failure of Client to approve changes or otherwise respond in a timely manner may result
in: (i) delay in the Product Availability Date; or (ii) loss of a Production slot in Catalent’s schedule; but in either case shall not relieve Client of its obligations to pay Catalent for all activities described in the applicable
Project Plan, including any lost Production slot. 

  

			
	CONFIDENTIAL INFORMATION	  	Page 14 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	3.10.2	 Product-Specific Changes. If Facility, equipment, process or system changes are required of Catalent as
a result of requirements set forth by the FDA or any other applicable Regulatory Authority, and such changes apply exclusively to the Production and supply of one or more Products, then Client and Catalent will review such requirements. If Client
agrees in writing to such changes, then Client shall bear [***] percent of the reasonable costs of implementation thereof. If Client does not agree to such regulatory changes, Client may terminate this Agreement upon written notice to Catalent, in
which case Client shall pay Catalent for all activities described in the applicable Project Plan, including any Missed Slot, in each case, if required under and in accordance with Section 3.8. 

 

	 	3.10.3	 General Changes. If such changes apply generally (i.e., to one or more Products as well as to other
products Produced by Catalent for itself or for third parties), and Client agrees to such regulatory changes, then Catalent shall make such changes. If Client does not agree to such regulatory changes, Client may terminate this Agreement upon
written notice to Catalent, in which case Client shall pay Catalent for all activities described in the applicable Project Plan, including any Missed Slot, in each case, if required under and in accordance with Section 3.8.

  

	 	3.11.	 Delivery Terms. Product shall be delivered to Client EXW (Incoterms, 2010) Facility, addressed to
a location designated by Client. Product shall be delivered to a common carrier designated by Client on the shipment request form or Project Plan, at Client’s expense. Client shall procure, at its cost, insurance covering damage or loss to the
Product during shipping. Title for Product shall pass to Client upon Catalent’s Quality Disposition of Product. If Catalent arranges shipping or performs similar loading and/or logistics services for Client at Client’s request, such
services are performed by Catalent as a convenience to Client only and do not alter the terms and limitations set forth in this section. Catalent shall not be responsible for Product in transit, including any cost of insurance or transport fees for
Product, or any risks associated with transit or customs delays, storage and handling. 

  

	 	3.12.	 Audit. During the Term and for one (1) year thereafter, once per calendar year upon [***]
days prior written notice, Client through its personnel or its designated representatives shall have the right to conduct an audit of that portion of each Facility used in the Production or performance of the Services during normal business hours to
review Catalent’s Production operations and to assess its compliance with CGMP, Applicable Laws and the Quality Agreement. Catalent shall provide Client with copies of Catalent’s Production

  

			
	CONFIDENTIAL INFORMATION	  	Page 15 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	
records relating to the Product, including Batch documentation and other requested information, to be used for the purposes of the audit. In the event there have been material quality issues with
Product or Production, Client may reasonably require more frequent audits of that Facility. However, if Catalent has failed to correct any discovered non-conformance (or taken reasonable measures to implement
a plan to correct the non-conformance) within [***] days of the event or audit which provided Catalent with notice of such non-conformance, Client will have the right to
terminate the Agreement pursuant to Section 10.2.1. Notwithstanding the foregoing notice period, for purposes of confidentiality, safety and to avoid the possibility of contamination, if a third party’s product is being manufactured during
the time that Client intends to conduct an audit, such audit may be reasonably delayed upon at least [***] days’ prior written notice to Client. When conducting an audit, each of Client’s representatives will: (a) be subject to a
nondisclosure obligation at least as restrictive as the obligations contained in Article 8 (“Confidentiality and Non-Solicitation of Employees”) (b) follow such security and Facility access
procedures as reasonably designated by Catalent; (c) be accompanied by a Catalent representative; (d) provided that Catalent has given Client notice in accordance with the previous sentence, not enter areas of the Facility at times when
any third party’s products are being manufactured to assure protection of the Catalent Confidential Information or the confidential information of a third party; and (e) use reasonable efforts to avoid disrupting Catalent’s
operations. In addition to an audit by Client, Catalent agrees to reasonably cooperate with applicable Regulatory Authorities and shall permit reasonable Product-specific inspections by such Regulatory Authorities. While Catalent will provide access
to the Facility as set forth herein for the purposes of this Section 3.12, for the avoidance of doubt, access to classified (for GMP purposes) areas of the Facility, areas that do not relate to the Services, and areas in which confidential work
for other Catalent customers is taking place is at Catalent’s sole discretion. 

  

	 	3.13.	 Dedicated Equipment. 

 

	 	3.13.1	 Selection and Procurement. To the extent that Catalent is required to purchase any
Dedicated Equipment, Catalent shall select and procure the Dedicated Equipment at Client’s sole cost [***]. Catalent shall use [***] efforts to determine whether the Dedicated Equipment conforms to the applicable specifications and will work in
the Facility for purpose stated in the Project Plan. 

  

			
	CONFIDENTIAL INFORMATION	  	Page 16 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	3.13.2	 Use and Storage of Dedicated Equipment. Catalent shall use and store the Dedicated Equipment in
accordance with any written instructions prescribed by Client or the manufacturer of the Dedicated Equipment, and shall perform such routine maintenance and storage for the Dedicated Equipment as is reasonably required by such written instructions
and be reimbursed by Client for routine maintenance and storage as set forth in a Project Plan. All costs for any extraordinary or non-routine maintenance that may be required will be approved in advance by
Client, and the appropriate Project Plan will be revised to reflect any additional maintenance costs that may be required during the Term. Except: (i) in connection with such routine maintenance and storage; or (ii) as directed in writing
by Client; Catalent shall not make any alterations, additions or improvements to the Dedicated Equipment. All directed alterations, additions or improvements made to the Dedicated Equipment will be at Client’s sole cost and expense.

  

	 	3.13.3	 Ownership and Risk of Loss; Disposition of Equipment. Client shall own and continue to own
all right, title and interest in and to any Dedicated Equipment. Client assumes any risk of loss, damage, theft or destruction of the Dedicated Equipment while that Dedicated Equipment is in Catalent’s possession or on Catalent’s premises;
except that Client hereby expressly disclaims liability, and Catalent shall be liable, for any and all loss, damage, theft or destruction of Dedicated Equipment resulting from Catalent’s negligence, gross negligence, or willful misconduct. Upon
termination or expiration of this Agreement, Client shall have the right and obligation, upon reasonable notice, to reclaim possession of such Dedicated Equipment at its sole expense (including all costs of disconnection, removal, physical transfer
and any subsequent reinstallation and requalification costs). Catalent shall reasonably cooperate with Client to remove and return such Dedicated Equipment to Client in accordance with Client’s written instructions and shall invoice Client for:
(i) direct costs incurred; and (ii) any damage other than reasonable wear and tear to the Facility incurred as a result of the installation and/or removal of the Dedicated Equipment. Notwithstanding the above, upon termination or
expiration of this Agreement, Client may offer to sell to Catalent, or Catalent may offer to purchase from Client, the Dedicated Equipment at its then depreciated cost or fair market value, whichever is less. Neither Catalent nor Client shall be

  

			
	CONFIDENTIAL INFORMATION	  	Page 17 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	
obligated to make or accept such offers. In the event that Client has not removed the Dedicated Equipment within [***] days after reasonable notice, the Dedicated Equipment shall be deemed to be
abandoned and Catalent may dispose of it or use it as it sees fit. 

  

	 	3.14.	 Product Testing. 

 

	 	3.14.1	 Testing. Catalent (or one or more of its Affiliates) shall test, or cause to be tested by third party
testing facilities audited and approved by Catalent, in accordance with the Product Specifications, each Batch of Product Produced pursuant to this Agreement before delivery to Client. A Certificate of Analysis for each Batch of Product delivered to
Client shall set forth the items tested by Catalent, specifications, and test results. Catalent shall send, or cause to be sent, such certificates along with one (1) copy of the Batch Record Package to Client prior to or at the same time of
shipment of Product to Client and within [***] calendar days after the date of fill if such Batch requires no investigations and/or additional testing. For the avoidance of doubt, Client is solely responsible for final release of each lot of the
Product. 

  

	 	3.14.2	 Stability Testing. At Client’s cost and expense, Catalent or a party selected by Client may perform
all stability testing required to be performed on Production Batches of Product. If performed by Catalent, such testing shall be performed in accordance with the procedures set out in the Product-specific Client-Specific SOPs for the stability
protocol and the Project Plan. 

  

	4.	 Nonconforming Product. 

 

	 	4.1.	 Product Conformity.  

 

	 	4.1.1	 Testing and Acceptance. Subject to Section 4.4 (“Nonconforming Development/Engineering
Batch”), Client shall have [***] calendar days from receipt by Client of: (i) representative samples of Product intended for release testing by Client; (ii) the Batch Record Package; or (iii) each Unit of Product, to determine
whether such Product (a) conforms to the relevant Product Specifications and (b) was manufactured in compliance with CGMP, as applicable (collectively the “Product Requirements”). If Client believes any shipment

  

			
	CONFIDENTIAL INFORMATION	  	Page 18 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	
of Product does not conform to the Product Requirements (“Nonconforming Product”), then Client shall give Catalent written notice thereof as soon as practicable but in no event
later than [***] days from the date of such determination by Client (an “Exception Notice”) and shall, unless otherwise directed by Catalent, return the Product (if it was shipped) for further testing by Catalent. Failure to timely
provide an Exception Notice and return of the Unit for further testing by Catalent shall constitute an acceptance by Client of such Unit; [***], that [***] be [***] with respect to [***] that are not [***] by the [***] of [***] and [***]. Catalent
shall conduct its own testing of the rejected Product or Unit(s), as applicable, within [***] days of receipt thereof, and if Catalent agrees, or it is determined pursuant to Section 4.1.2 (“Disputes”), that the Product is a
Nonconforming Product as a result of Catalent’s negligence, gross negligence, or willful misconduct (“Catalent Nonconforming Product”), the applicable provisions of Section 4.2 (“Remedies for Nonconforming
Product”) shall apply. If, after conducting its own testing, Catalent determines, or it is determined pursuant to Section 4.1.2 (“Disputes”), that the Nonconforming Product is not a Catalent Nonconforming Product, then the
applicable provisions of Section 4.3 (“Remedies for Nonconforming Product”) shall apply. 

  

	 	4.1.2	 Disputes. If the Parties disagree as to whether Product meets Product Requirements and/or is
Nonconforming Product or Catalent Nonconforming Product, and this is not resolved within [***] days of Catalent’s receipt of an Exception Notice, the Parties shall cause a mutually acceptable independent third party to review records and test
data and to perform comparative tests and/or analyses on samples of such Product, including (as appropriate) any Client Materials, Raw Materials, Process Consumables, and Components. The independent party’s results as to whether Product or Unit
meets Product Requirements or is a Nonconforming Product or Catalent Nonconforming Product, and the cause of any nonconformity, shall be final and binding. Unless otherwise agreed to by the Parties in writing, the costs associated with such testing
and review shall be borne by Catalent if Product is deemed by the independent party to be Catalent Nonconforming Product, and by Client in all other circumstances. For avoidance of doubt, where the cause of nonconformity cannot be determined or
assigned, the Product shall not be deemed to be Catalent Nonconforming Product. 

  

			
	CONFIDENTIAL INFORMATION	  	Page 19 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	4.2.	 Remedies for Catalent Nonconforming Product. If a Product is determined to be Catalent
Nonconforming Product (whether by agreement of Catalent pursuant to Section 4.1 (“Product Conformity”) or by an independent expert pursuant to Section 4.1.2 (“Disputes”)), the Parties will negotiate in good faith
whether such Catalent Nonconforming Product shall be returned to Catalent, destroyed, or retained by Client, and the terms that shall govern the chosen course of action. Additionally: 

 

	 	4.2.1	 Drug Product: If the Drug Substance met or is deemed to meet Product Requirements, but the Drug
Product constitutes Catalent Nonconforming Product, [***] shall [***] the [***] at [***] for [***]. In the re-performance of its Drug Product Services, Catalent shall use replacement Bulk Drug Substance, Raw
Materials, Process Consumables, and Components. Regardless of whether such replacement Bulk Drug Substance, Raw Materials, Process Consumables, and Components are provided by Client or Catalent, [***] the [***] of the [***] and [***] the [***] of
the [***] , and [***]. The remedies described in this Section 4.2.1 shall be Client’s sole remedies under this Section 4.2.1. 

  

	 	4.2.2	 Replacement. In each such case, Catalent shall use [***] efforts to replace such Nonconforming Product
in a reasonable time given any commitments to other Catalent clients or contractually obligated capacity constraints.  

  

	 	4.3.	 Remedies for Other Nonconforming Product. In the event a Product is determined to be
Nonconforming Product (whether by agreement of Catalent pursuant to Section 4.1 (“Product Conformity”) or by an independent expert pursuant to Section 4.1.2 (“Disputes”)), but is not determined to be Catalent
Nonconforming Product, the Parties will negotiate in good faith whether such Nonconforming Product shall be returned to Catalent, destroyed, or retained by Client, and the terms that shall govern the chosen course of action. Additionally:

  

	 	4.3.1	 Catalent shall re-perform the Services with respect to the
Nonconforming Product at Client’s option and expense with Client bearing the cost of Bulk Drug Substance, other Raw Materials, Process Consumables, Components, and the Services of Catalent including the Batch Price for the Nonconforming
Product. Client shall be responsible for the cost of each Batch of such Nonconforming Product. 

  

			
	CONFIDENTIAL INFORMATION	  	Page 20 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	4.3.2	 In each such case, Catalent shall use [***] efforts to replace such Nonconforming Product in a
reasonable time given any commitments to other Catalent clients or contractually obligated capacity constraints. 

  

	 	4.4.	 Nonconforming Development/Engineering Batch. Client shall be responsible for the cost of each
Development/Engineering Batch, whether or not Product from the Development/Engineering Batch is delivered (provided that Client shall not be responsible for the cost of a Development/Engineering Batch that was not delivered because of a failure that
was caused by the gross negligence of Catalent or as a result of a Catalent equipment or facility malfunction (“Catalent Development/Engineering Batch Failure”)). Catalent and Client shall cooperate in good faith to resolve any
problems causing any out-of-Specification Development/Engineering Batch. Except with respect to a Catalent Development/Engineering Batch Failure, Catalent shall have no
obligation to re-perform any Services for a Development/Engineering Batch. If Catalent re-performs any Services, and Client approves such re-performance in writing, Client shall be responsible for the cost of all Raw Materials and/or Components and Client shall supply Catalent with sufficient quantities of any Client-Supplied Raw Materials and
Components in order for Catalent to re-perform such Services. 

  

	 	4.5.	 Nonconforming Client Materials. If a Product’s failure to meet the Product Requirements (whether or
not such Product has been given a Quality Disposition of “released”) is the sole and direct result of nonconforming Client Materials (including by not limited to Bulk Drug Substance), then such nonconformity shall not be deemed the
responsibility of Catalent for purposes of this Article 4 (“Nonconforming Product”), and notwithstanding Section 4.1 (“Product Conformity”) above, Client shall pay Catalent’s invoice for such Product, and Catalent shall
not be required to bear the cost of replacing the nonconforming Product pursuant to Section 4.2 (“Remedies for Catalent Nonconforming Product”). 

 

	5.	 Price and Payment. 

 

	 	5.1.	 Product Price. The price to be paid by Client for Units of Product (“Price”)
shall be set forth in the Project Plan, accepted purchase order, or as otherwise agreed to in writing between the Parties. Each calendar year, Catalent may, at its sole discretion, increase or decrease the Price of any Product that is not covered by
a Firm Order as of the effective date of the Price increase or decrease. 

  

			
	CONFIDENTIAL INFORMATION	  	Page 21 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	5.2.	 Cost Reimbursement. For all pass-through and out-of-pocket costs specified in the Project Plan (which may include but is not limited to Raw Materials, Catalent-Supplied Components, filters, containers,
Product-contact disposables, and Dedicated Equipment) Client shall reimburse Catalent, at Catalent’s cost [***]. 

  

	 	5.3.	 Payment Terms. Catalent shall generate invoices for all fees and cost reimbursements. Invoices
for Product will be sent in accordance with the milestones set forth in the Project Plan, and in any case not later than Catalent’s Quality Disposition of each Batch of Product. Each such invoice will provide a reasonable level of detail and
itemize the status of each activity and milestone as detailed in the Project Plan. Invoices for cost reimbursement will be sent not less than monthly and include reasonable documentation of costs incurred. Client shall pay undisputed invoices [***]
of the invoice date. If any payment is not received by Catalent by its due date, then Catalent may, in addition to other remedies available at equity or in law, charge interest [***] on the outstanding sum until paid in full, calculated from the
scheduled payment due date forward; provided that in no event shall such annual rate exceed the maximum interest rate permitted by Applicable Laws in regard to such payments. Such payments when made shall be accompanied by all interest so accrued.
Client shall make all payments electronically through the Automated Clearing House (ACH) Network in U.S. Dollars, or otherwise as directed in the applicable invoice. 

 

	 	5.4.	 Regulatory Services Price. The price to be paid by Client for regulatory services shall be set forth in
a Project Plan. 

  

	 	5.5.	 Default in Payment Obligations. In addition to all other remedies available to Catalent in the event of
a Client default, if Client fails to make undisputed payments as required hereunder, Catalent may refuse all further orders and may refuse to Produce any Product until Client’s account is paid in full. 

 

	 	5.6.	 Insurance. Each Party shall, at its own cost and expense, obtain and maintain in full force and
effect during the Term the following: (A) Commercial General Liability Insurance with a per occurrence limit of $[***] and an annual aggregate limit of $[***]; (B) Products and Completed Operations Liability Insurance with a per occurrence
limit of not less than $[***]; (C) Workers’ Compensation Insurance with statutory amounts and Employers Liability Insurance with limits of not less than $[***] per accident; and (D) Auto Liability insurance for owned, hired and non-owned vehicles in a minimum amount of $[***] combined single limit. Client shall, at its own cost and expense, obtain and maintain in full force and effect during the Term, All Risk Property Insurance, including
transit coverage, in an amount equal to the full replacement value of its property at all times whether in transit to, or from, a Facility, between Facilities, or present at a Facility. Client shall obtain a

  

			
	CONFIDENTIAL INFORMATION	  	Page 22 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	
waiver of subrogation clause from its property insurance carrier in favor of Catalent. Each Party may self-insure all or any portion of the required insurance as long as, together with its
Affiliates, its US GAAP net worth is greater than $[***] or its annual EBITDA (earnings before interest, taxes, depreciation and amortization) is greater than $[***]. If any required insurance policy is written on a claims-made basis, such
policy shall be maintained throughout the Term and for a period of at least [***] years thereafter. Each Party shall be named as an additional insured within the other Party’s products liability insurance policies. Waivers of subrogation
and additional insured status obligations will operate the same whether insurance is carried through third parties or self-insured. Upon the other Party’s written request from time to time, each Party shall promptly furnish to the other Party a
certificate of insurance or other evidence of the required insurance or qualification to self-insurance in accordance with the requirements of this Article 5 (“Price and Payment”). Each insurance policy that is required under this
Agreement shall be obtained from an insurance carrier with an A.M. Best or equivalent rating of at least A- VII or an S&P rating of A. 

 

	 	5.7.	 Taxes. Unless otherwise indicated in writing by Catalent, all prices and charges are exclusive of any
applicable taxes, levies, import duties, Goods and Services Tax (GST), Value Added Tax (VAT), and fees of whatever nature, imposed by or under the authority of any governmental body, all of which shall be paid by Client (other than taxes on
Catalent’s net income). If applicable, Indiana sales tax shall be charged on all applicable transactions unless Client has provided to Catalent a properly completed Indiana Exemption Certificate (Form
ST-105). To the extent that Client owns any Dedicated Equipment or other personal property located at the Facility that is subject to property tax, Catalent may be obligated to report such property and Client
shall be obligated to file and pay all applicable Monroe County, Indiana property taxes. If any deduction or withholding in respect of any tax or otherwise is required by law to be made from the amounts payable under this Agreement, Client shall be
obliged to pay to Catalent such greater sum as will leave Catalent, after such required deduction or withholding is made, with the same amount as it would have been entitled to receive in the absence of any such required deduction or withholding
obligation. 

  

	6.	 Representations and Warranties. 

 

	 	6.1.	 Mutual Representations and Warranties. Each Party hereby represents and warrants to the other
Party as follows: 

  

	 	6.1.1	 Such Party is duly organized, validly existing and in good standing under the laws of the jurisdiction
in which it is organized. 

  

			
	CONFIDENTIAL INFORMATION	  	Page 23 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	6.1.2	 Such Party (i) has the requisite power and authority and the legal right to enter into this
Agreement and to perform its obligations hereunder, and (ii) has taken all necessary action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder. 

 

	 	6.1.3	 This Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal,
valid, binding obligation, enforceable against such Party in accordance with its terms. 

  

	 	6.1.4	 All necessary consents, approvals and authorizations of all governmental authorities and other Persons
required to be obtained by such Party in connection with this Agreement have been obtained. 

  

	 	6.1.5	 The execution and delivery of this Agreement and the performance of such Party’s obligations
hereunder (i) do not and will not conflict with or violate any requirement of Applicable Laws or regulations and (ii) do not and will not conflict with, or constitute a default under, any contractual obligation of such Party. Catalent has
informed Client, and Client acknowledges, that Catalent is a US Government contractor and that in an emergency declared by the US Government, Catalent may be obligated to give US Government production requirements priority over other production
orders. If this occurs, it shall not be deemed a breach by Catalent of its representations and warranties under this clause, or under any other section of this Agreement. 

 

	 	6.1.6	 Each Party represents, warrants and covenants that it shall not employ, contract with, or retain any
person directly or indirectly to perform any services under this Agreement if: (i) such person is presently debarred by the FDA pursuant to 21 U.S.C. § 335a and b or its successor provisions, or the party has knowledge that such a person
is under investigation by the FDA for debarment; or (ii) such a person has a disqualification hearing pending or has been disqualified by the FDA pursuant to 21 CFR § 312.70 or its successor provisions. In addition, each Party
represents, warrants and 

  

			
	CONFIDENTIAL INFORMATION	  	Page 24 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	
covenants that it has not and shall not engage in any conduct or activity which could reasonably lead to any of the above-mentioned disqualification or debarment actions. If, during the Term,
either party or any person employed or retained by it to perform the Services: (A) comes under investigation by the FDA for a debarment action or disqualification; (B) is debarred or disqualified; or (C) engages in any conduct or
activity that could lead to any of the above-mentioned disqualification or debarment actions, such Party shall immediately notify the other Party of same. 

 

	 	6.1.7	 No transaction or dealing under this Agreement shall be conducted with or for an individual, entity or a
country that is designated as the target of any sanction, restriction or embargo administered by the United Nations, European Union, United Kingdom or United States of America. 

 

	 	6.2.	 Representations and Warranties of Client. Client further represents and warrants, and covenants that:

  

	 	6.2.1	 Client has lawful access to and the right to license or sublicense the Client Confidential Information,
Client Intellectual Property Rights and Client Materials to Catalent under this Agreement. 

  

	 	6.2.2	 Client is not subject to any written claim or notice of infringement or misappropriation of any third
party intellectual property rights relating to the Client Confidential Information, Client Intellectual Property Rights or Client Materials used by Catalent under this Agreement. 

 

	 	6.2.3	 [***] each of the making, having made, use or importation of the Product and/or the Client Materials in
accordance with the Project Plan and this Agreement do not infringe or misappropriate any third party intellectual property rights. 

  

	 	6.2.4	 The biological and chemical properties of the Client Materials have been evaluated prior to the
Effective Date and, to Client’s knowledge, the Client Materials are safe and non-hazardous for purposes of the Services to be performed hereunder. 

  

			
	CONFIDENTIAL INFORMATION	  	Page 25 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	6.3.	 Representations and Warranties of Catalent. Catalent shall perform all Services in accordance with
Applicable Laws. Except with respect to a Development/Engineering Batch, Catalent represents, warrants and covenants that: (a) the Production shall be performed in accordance with Section 3.2 (“Performance”) and (b) the
Product when made available at Catalent’s shipping docks shall: (i) meet Product Specifications; (ii) have been Produced in accordance with CGMP and Applicable Laws; and (iii) at the time of delivery, shall be free and clear of
any lien or encumbrance. Catalent further represents, warrants, and covenants that (A) Catalent owns, or holds sufficient rights to use for the purposes of Production of the Product, all Catalent Intellectual Property used by Catalent in the
Production of the Product pursuant to this Agreement, (B) such Catalent Intellectual Property does not infringe the intellectual property rights of any third, and (C) all Permitted Subcontractors utilized by Catalent in fulfillment of its
obligations under this Agreement are obligated to assign any intellectual property developed hereunder to Catalent. EXCEPT FOR ANY REPRESENTATIONS AND WARRANTIES IN THIS AGREEMENT, CATALENT HEREBY EXPRESSLY DISCLAIMS ALL OTHER REPRESENTATIONS OR
WARRANTIES, WHETHER EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR ARISING FROM A COURSE OF DEALING OR USAGE OR TRADE PRACTICE, WITH REGARD TO ANY PRODUCT DELIVERED
HEREUNDER, WHETHER USED ALONE OR IN COMBINATION WITH OTHER SUBSTANCES OR NON-INFRINGEMENT OF THE PATENT RIGHTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF ANY OTHER PERSON. 

 

	7.	 Indemnification; Limitation of Liability; Waiver of Subrogation. 

 

	 	7.1.	 Client Indemnification. Subject to the limitations set forth in Section 7.4, Client shall
indemnify, defend and hold harmless Catalent against any Damages, whether or not foreseeable or in the contemplation of Catalent or Client, that Catalent suffers as a result of any third party Claims arising out of: (a) any material breach of
the representations and warranties set forth in Sections 6.1 (“Mutual Representations and Warranties”) and 6.2.4; (b) the distribution or use of the Product Produced by Catalent under this Agreement; (c) Product Liability Claims;
(d) negligence (active, passive or imputed), gross negligence or willful misconduct of Client in relation to the use, processing, storage or sale of the Product Produced by Catalent under this Agreement; and/or (e) any claims by third
parties alleging Catalent’s use of the Client Materials, Client Confidential Information, Client Intellectual Property Rights or the Product Specifications in accordance with the Project Plans and this Agreement infringes any intellectual
property rights of any third party (whether or not Client knew or should have known about such alleged infringement). This indemnification obligation shall not apply to the extent that such Claims arise

  

			
	CONFIDENTIAL INFORMATION	  	Page 26 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	
out of: (i) Catalent’s production techniques while performing the Services; or (ii) a modification of the Client Materials, Client Confidential Information, Client Intellectual
Property Rights or the Product Specification that is not approved by Client. Client shall have no obligation to indemnify, defend or hold harmless Catalent in accordance with this Section 7.1 to the extent that any Damages are caused by
Catalent’s negligence (active, passive or imputed), gross negligence or willful misconduct or the breach by Catalent of any warranty, representation, or covenant made by Catalent in this Agreement. 

 

	 	7.2.	 Catalent Indemnification. Subject to the limitations set forth in Section 7.4, Catalent
shall indemnify, defend and hold harmless Client against any Damages, whether or not foreseeable or in the contemplation of Client or Catalent, that Client may suffer as a result of any third party claims, suits or actions arising from:
(a) Catalent’s breach of the representations and warranties in Sections 6.1 (“Mutual Representation and Warranties”) and 6.3 (“Representations and Warranties of Catalent”); (b) negligence (active, passive or imputed),
gross negligence or willful misconduct of Catalent in performance of the Services; and/or (c) any claims by third parties alleging Catalent’s Production techniques while performing the Services infringe any intellectual property rights of
any third party (whether or not Catalent knew or should have known about such alleged infringement). This indemnification obligation shall not apply to the extent the Damages are a result of: (i) Client’s negligence (active, passive or
imputed); (ii) Catalent’s use of an application or production technique that has been provided by Client; or (iii) Catalent’s use of Client Materials. 

 

	 	7.3.	 Procedure for Indemnification. A Party (the “Indemnitee”) that intends to claim
indemnification under Sections 7.1 (“Client Indemnitee Indemnification”) or 7.2 (“Catalent Indemnification”) shall promptly notify the other Party (the “Indemnitor”) of any Claim for which the Indemnitee
intends to claim such indemnification. The Indemnitee shall have the right to retain its own counsel, at its own cost, to participate in the defense of any Claim. The indemnity obligations under Sections 7.1 (“Client Indemnification”) and
7.2 (“Catalent Indemnification”) shall not apply to amounts paid in settlement of any claim, demand, action or other proceeding if such settlement is effected without the prior express written consent of the Indemnitor, which consent shall
not be unreasonably withheld or delayed. The failure to deliver notice to the Indemnitor within a reasonable time after notice of any such Claim, or the commencement of any such action or other proceeding, if materially prejudicial to its ability to
defend such claim, demand, action or other proceeding, shall relieve such Indemnitor of any liability to the Indemnitee under Sections 7.1 (“Client Indemnification”) and 7.2 (“Catalent Indemnification”) with respect thereto, but
the omission so to deliver notice to 

  

			
	CONFIDENTIAL INFORMATION	  	Page 27 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	
the Indemnitor shall not relieve it of any liability that it may have to the Indemnitee otherwise than under Sections 7.1 (“Client Indemnification”) and 7.2 (“Catalent
Indemnification”). The Indemnitor may not settle or otherwise consent to an adverse judgment in any such Claim without the prior express written consent of the Indemnitee, which consent shall not be unreasonably withheld or delayed. The
Indemnitee, its employees and agents shall reasonably cooperate with the Indemnitor and its legal representatives in the investigation and defense of any claim, demand, action or other proceeding covered by this Section 7.3 (“Procedure for
Indemnification”). 

  

	 	7.4.	 Limitation of Liability. 

 

	 	7.4.1	 DISCLAIMER OF SPECIAL DAMAGES. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY OR TO ANY
THIRD PARTY UNDER THIS AGREEMENT FOR ANY PUNITIVE DAMAGES OR SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGES (INCLUDING LOST PROFITS, BUSINESS OR REVENUE) EVEN IF ADVISED OR AWARE OF THE POSSIBILITY OF SUCH DAMAGES. 

 

	 	7.4.2	 Direct Damage Limitation. The liability of Catalent to Client, its permitted assigns and successors in
interest, for any Damages suffered by Client or its permitted assigns and successors in interest, arising as a direct result of a breach of this Agreement, or of any other liability, including misrepresentation and negligence, arising out of this
Agreement and the Services provided hereunder, including the production or supply of Product and Catalent’s liability under Section 7.2 (“Catalent Indemnification”), shall be limited to: (i) [***] the [***] amount [***] by [***]
from [***] for [***] for the [***] that [***] to the [***]; (ii) [***] dollars ($[***]) in the event of loss of [***] as set forth in [***]; or (iii) [***] Dollars ($[***]) (in the case of [***] not covered by (i) or (ii) above) [***].

  

	 	7.5.	 Abatement. Notwithstanding anything to the contrary in this Agreement, in the event that
Production is held, in a suit or proceeding, to infringe any intellectual property rights of a third party (or to constitute the misappropriation of a trade secret of a third party) and Production is enjoined, or Catalent has an objective basis
(confirmed by an opinion of its legal counsel) for believing that it is likely to be found to infringe or constitute a misappropriation, or is likely to be enjoined, then Catalent shall, at its option,

  

			
	CONFIDENTIAL INFORMATION	  	Page 28 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	
either: (i) procure the right to continue Production; or (ii) modify the Production so that it becomes non-infringing or no longer constitutes a
misappropriation, provided that such modification has no adverse effect on Client hereunder; provided, however, that if (i) and (ii) are not reasonably practicable, then Catalent shall notify Client and Client shall have the right, in its sole
discretion, to terminate this Agreement, effective upon the date the notice is given, by giving Catalent prior written notice of the termination. Client shall have no obligations to make any additional payments, including any payments for Firm Order
made but not fulfilled, after the effective date of such termination. 

  

	 	7.6.	 Waiver of Subrogation. All Catalent Supplied Components and equipment (other than Dedicated Equipment
owned by Client) used by Catalent in the Production of Product (collectively, “Catalent Property”) shall at all times remain the property of Catalent and Catalent assumes risk of loss for such property until delivery of
Product to a common carrier as specified under Section 3.11 (“Delivery Terms”). Catalent hereby waives any and all rights of recovery against Client, or against its directors, officers, employees, agents or representatives, for any
loss or damage to Catalent Property to the extent the loss of damage is covered or could be covered by insurance (whether or not such insurance is described in this Agreement). Client assumes all risk of loss for all Client Materials, Dedicated
Equipment owned by Client, and all Product that are in Client’s possession (collectively, “Client Property”). Client hereby waives any and all rights of recovery against Catalent, or against its directors, officers,
employees, agents or representatives, for any loss or damage to the Client Property to the extent the loss of damage is covered or could be covered by insurance (whether or not such insurance is described in this Agreement). 

 

	 	7.7.	 Limitations an Essential Element of the Agreement. The Parties are willing to enter into this Agreement
only in consideration of and in reliance upon the provisions of this Agreement limiting their exposure to loss or liability. Such provisions are an essential part of the bargain underlying this Agreement and have been reflected in the pricing and
other consideration specified in this Agreement. Both Parties understand and agree that the exclusion of warranties, limitation of liability and the limitation of remedies allocate risks between the Parties as authorized under Applicable Laws.

  

	8.	 Confidentiality and Non-Solicitation of Employees.

  

	 	8.1.	 Confidential Information. Each Party agrees that during the Term of this Agreement and for a
period of [***] years thereafter, it will keep the Confidential Information of the other Party secret and confidential in accordance with the terms and conditions of this Agreement, respect the other

  

			
	CONFIDENTIAL INFORMATION	  	Page 29 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	
Party’s proprietary rights therein and make use of and permit to be made use of such information and material only as necessary to perform its obligations and exercise its rights under this
Agreement. Neither Party may disclose or permit the Confidential Information of the other Party to be disclosed to any third party except as expressly provided herein without the other Party’s prior written consent. 

 

	 	8.2.	 Disclosure of Confidential Information. Client and Catalent shall grant access to the other Party’s
Confidential Information only to its Affiliates, employees and Permitted Subcontractors who reasonably need to know such information for purposes such Party’s exercise of its rights or performance of its obligations under this Agreement and who
are subject to written obligations of confidentiality with respect to which Confidential Information no less restrictive than those set forth in this Article 8. 

 

	 	8.3.	 Exceptions to Confidentiality. The obligations of Article 8 shall not apply to Confidential
Information to the extent that it: 

  

	 	8.3.1	 is now, or hereafter becomes, through no act or failure to act on the part of the receiving Party in
breach of Article 8 (“Confidential Information and Non-Solicitation of Employees”), generally known or available; 

 

	 	8.3.2	 is known by the receiving Party at the time of receiving such Confidential Information, as shown by
contemporaneous written records; 

  

	 	8.3.3	 is furnished after the Effective Date to the receiving Party by a third party, without breach of and not
subject to any obligation of confidentiality; or 

  

	 	8.3.4	 is independently developed by the receiving Party without use of or reference to Confidential
Information of the other Party, as shown by independent written records, contemporaneous with such development. 

 In
addition, the receiving Party may disclose the disclosing Party’s Confidential Information to the extent that it is compelled to do so under any statutory, regulatory, stock exchange or similar legislative requirement or court order, provided,
however, that (i) the receiving Party gives the disclosing Party prior written notice of such required disclosure (to the extent permitted) and assists the disclosing Party in its reasonable efforts to prevent or limit such disclosure; and
(ii) the Confidential Information so disclosed otherwise remains the Confidential Information of the disclosing Party for the purposes of Article 8 (“Confidentiality and Non-Solicitation of
Employees”). 

  

			
	CONFIDENTIAL INFORMATION	  	Page 30 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	8.4.	 Return of Confidential Information. Upon any expiration or termination of this Agreement, each
Party will use diligent efforts (including without limitation a diligent search of files and computer storage devices) to return or destroy all Confidential Information of the other Party and all copies, summaries, compilations, extracts or other
derivatives thereof, except to the extent such Confidential Information is necessary to exercise any right surviving termination of this Agreement. Additionally, each Party will be allowed to keep one archival copy of any Confidential Information of
the other Party solely for record keeping and for the purpose of determining its rights and obligations hereunder. 

  

	 	8.5.	 Restrictions on Soliciting Catalent Employees. During the Term of the Agreement and for [***]
months after the Agreement terminates or expires, Client shall not, directly or indirectly, solicit, hire, employ or attempt to solicit, hire or employ any person who is or was an employee of Catalent during the Term (or the following
[***] months), or in any other way directly or indirectly seek to solicit, induce, bring about, influence, promote, facilitate, or encourage any such individual to work for Client or any party other than Catalent. The foregoing limitation shall
not apply with respect to any general solicitations for employment made by Client. 

  

	 	8.6.	 Remedies. Each Party acknowledges and agrees that the other Party may not have an adequate remedy
at law for a violation of this Article 8 (“Confidentiality and Non-Solicitation of Employees”) and therefore shall be entitled to seek enforcement of this Article 8 (“Confidentiality
and Non-Solicitation of Employees”) by temporary or permanent injunctive or mandatory relief obtained in any court of competent jurisdiction without the necessity of proving Damages, and without prejudice
to any other rights and/or remedies which may be available to such Party at law or in equity. 

  

	 	8.7.	 Use of Name. Except as set forth in Section 9.6 (“Trademarks”), neither Party shall use
the name or trademarks of the other Party, except to the extent that a Party is permitted to use the Confidential Information of the other Party or required to do so pursuant to this Article 8 (“Confidentiality and Non-Solicitation of Employees”), without the prior written consent of such other Party, such consent not to be unreasonably withheld. Under no circumstances shall either Party state or imply in any promotional
material, publication or other published announcement that the other Party has tested or approved any product. 

  

			
	CONFIDENTIAL INFORMATION	  	Page 31 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	9.	 Intellectual Property. 

 

	 	9.1.	 Disclosure. Catalent shall disclose to Client any and all Product Inventions made pursuant to the
activities undertaken relating to this Agreement promptly after each such Invention is developed, conceived, or reduced to practice. 

  

	 	9.2.	 Catalent Intellectual Property Rights. As between the Parties, Catalent shall solely own all
right, title and interest in and to the Catalent Intellectual Property Rights. Catalent hereby grants Client a non-exclusive, perpetual, irrevocable, fully paid-up,
sublicensable, royalty-free license under the Catalent Intellectual Property Rights solely for the purpose of using, offering for sale, selling, exporting, and/or importing Product supplied by Catalent. Client shall not, without Catalent’s
prior written consent, use the Catalent Intellectual Property Rights for any purpose other than as stated herein. 

  

	 	9.3.	 Client Intellectual Property Rights. As between the Parties, Client shall solely own all right,
title and interest in and to the Client Intellectual Property Rights. Catalent shall not, without Client’s prior written consent, use the Client Intellectual Property Rights for any purpose other than Services as contemplated in this Agreement,
including in Section 2.3 (“License Grant”). 

  

	 	9.4.	 Inventions. All Project Inventions shall be owned by Catalent. Client hereby assigns and agrees
to assign all of its ownership rights in and to the Project Inventions to Catalent. To the extent that a Project Invention is patentable, Catalent shall have the right (but not the obligation) to file, prosecute and maintain any patents or patent
applications claiming or covering any Project Invention. All Product Inventions shall be owned by Client. Catalent hereby assigns and agrees to assign all of its ownership rights in and to the Product Inventions to Client. Client shall have the
right but not the obligation to file, prosecute and maintain any patents or patent applications claiming all Product Inventions. Each Party shall bear the expense of activities relating to its own filing, prosecution and maintenance of any patent or
patent applications provided for by this Section 9.4 (“Inventions”). Each Party shall execute all writings or take such acts, at the other Party’s expense, as may be reasonably required for either Party to fully enjoy the rights
and licenses granted pursuant to this Section 9.4 (“Inventions”).

  

	 	9.5.	 No Implied Licenses. Except as expressly set forth in this Agreement, nothing contained in this
Agreement shall be construed as granting, by implication, estoppel or otherwise, any licenses or rights under any patents or other intellectual property rights. Only licenses and rights granted expressly herein shall be of legal force and effect.

  

			
	CONFIDENTIAL INFORMATION	  	Page 32 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	9.6.	 Trademarks. 

 

	 	9.6.1	 Catalent License. Subject to the terms and conditions of this Agreement, Client grants to
Catalent a non-exclusive, non-sublicensable (except to Permitted Subcontractors) royalty free license during the Term to use the Client Trademarks for the sole purpose
of allowing Catalent to fulfill its responsibilities under this Agreement. Such license shall not be transferable in whole or in part. Catalent may only use the Client Trademarks in accordance with any usage guidelines that Client provides to
Catalent from time to time. Catalent agrees that all goodwill arising out of the use of the Client Trademarks will accrue to the sole benefit of Client. 

  

	 	9.6.2	 Client Ownership. Client shall be solely responsible for selecting, registering and enforcing the Client
Trademarks used to identify the Product, except as set forth in Section 9.6.1 (“Catalent License”), and shall have sole and exclusive rights in such Client Trademarks. 

 

	 	9.7.	 Ownership of Information. All information not in the public domain, including ideas, discoveries,
inventions, data, formulae, techniques, procedures for experiments and tests, designs, sketches, records, biological processes and analyses, whether or not patented or eligible for patent protection (“Information”) developed by
Catalent pursuant to this Agreement, including all interim reports and final reports, any data, records relating exclusively to Batches of the Product, and analytical methods and specifications and all copies thereof, shall be the sole property of
Client. Catalent shall provide to Client copies of Information and access to Information in accordance with the terms of this Agreement. All records generated by or delivered to Catalent that are not subsequently delivered to Client shall be
retained by Catalent for any retention period required by Applicable Laws. 

  

	10.	 Term and Termination. 

 

	 	10.1.	 Term. This Agreement shall be effective on the Effective Date and shall continue for thirty-six (36) months thereafter (the “Initial Term”), unless earlier terminated in accordance with the terms of this Agreement. This Agreement will be renewed for successive twelve
(12) month periods commencing at the expiration of the Initial Term and any extensions thereof unless either the Client or Catalent gives the other Party written notice of intent not to renew the Agreement at least ninety (90) days prior
to the expiration of the Initial Term or any extension thereof. The Initial Term as may be extended is referred to herein as the “Term.” Client may at any time terminate this Agreement for its convenience upon thirty (30) days
written notice to Catalent. 

  

			
	CONFIDENTIAL INFORMATION	  	Page 33 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	10.2.	 Termination for Breach. 

 

	 	10.2.1	 Generally. Except as provided in Section 10.2.2 (“Exhaustion”), the failure by a
Party (the “Defaulting Party”) to comply with any of the Defaulting Party’s material obligations under this Agreement shall entitle the other Party (the “Non-Defaulting
Party”) to give to the Defaulting Party notice specifying the nature of the default and requiring the Defaulting Party to cure such default. If such default is not cured within thirty (30) days after the receipt of such notice (or, if
such default reasonably cannot be cured within such period), the Non-Defaulting Party shall be entitled, without prejudice to any of the other rights conferred on it by this Agreement or available to it at
law, in equity or under this Agreement, to terminate this Agreement by giving further notice to the Defaulting Party, to take effect immediately upon delivery thereof. The right of either Party to terminate this Agreement, as provided in this
Section 10.2.1 (“Generally”), shall not be affected in any way by its waiver or failure to take action with respect to any previous default. 

  

	 	10.2.2	 Exhaustion. No default based on a claimed failure of any Product to conform to the Product
Specifications shall be the subject of a notice under Section 10.2.1 (“Generally”) until and unless all procedures and remedies specified in Article 4 (“Nonconforming Product”) shall have first been exhausted.
Furthermore, no inability to supply Client with Product caused by an event of Force Majeure shall be the subject of a notice under Section 10.2.1 (“Generally”). 

 

	 	10.3.	 Termination for Insolvency. Subject to any limitations imposed by applicable law, either Party shall
have the right to terminate this Agreement by giving notice to the other Party in the event that: 

  

	 	10.3.1	 Such other Party shall have: (i) voluntarily commenced any proceeding or filed any petition seeking
relief under the bankruptcy, insolvency or other similar laws of any jurisdiction, (ii) applied for, or consented to, the appointment of a receiver, trustee, custodian, sequestrator, conciliator, administrator or similar official for it or for
all or substantially all of its property, (iii) filed an answer admitting the material allegations of a petition filed against or in 

  

			
	CONFIDENTIAL INFORMATION	  	Page 34 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	
respect of it in any such proceeding, (iv) made a general assignment for the benefit of creditors of all or substantially all of its assets, (v) become unable generally, or admitted in
writing its inability, to pay all or substantially all of its debts as they become due, or (vi) taken corporate action for the purpose of effecting any of the foregoing; or 

 

	 	10.3.2	 An involuntary proceeding shall have been commenced, or any involuntary petition shall have been filed,
in a court of competent jurisdiction seeking: (i) relief in respect of such other Party, or of its property, under the bankruptcy, insolvency or similar laws of any jurisdiction, (ii) the appointment of a receiver, trustee, custodian,
sequestrator, conciliator, administrator or similar official for such other Party or for all or substantially all of its property, or (iii) the winding-up or liquidation of such other Party; and, in each
case, such proceeding or petition shall have continued undismissed for sixty (60) days or an order or decree approving or ordering any of the foregoing shall have continued unstayed, unappealed and in effect for thirty (30) days.

  

	 	10.4.	 Consequences of Termination.  

 

	 	10.4.1	 Payments Upon and After Termination. Upon expiration or termination of this Agreement for any reason
other than as a result of Catalent’s failure to comply with any of its material obligations under this Agreement or as set forth in Sections 3.11 or 7.5, Client shall pay Catalent for all work in process and Firm Orders (including all binding
Project Plans and purchase orders) that are in place as of the termination date. All such payments shall be made within [***] days of invoicing by Catalent. Unless this Agreement is terminated then as a result of Catalent’s failure to comply
with any of the its material obligations under this Agreement or as set forth in Sections 3.11 or 7.5, upon any termination (but not expiration) of this Agreement, Client shall reimburse Catalent for all costs and expenses incurred, and all non-cancelable commitments made, in the performance of Services, including (A) any costs incurred to wind down and cease any ongoing Services and (B) all costs for purchases made by Catalent on behalf of
Client. For the avoidance of doubt, if Client terminates this Agreement as a result of Catalent’s failure to comply with any of its material obligations under this Agreement, Client shall have no obligations to make any additional payments
(including any payments for Firm Order made but not fulfilled) under this Agreement. 

  

			
	CONFIDENTIAL INFORMATION	  	Page 35 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	10.4.2	 Effect of Termination. In the event of any termination or expiration of this Agreement, Catalent shall
provide reasonable assistance to Client to implement the transfer of Production responsibility for the Product to Client or its designee. Such reasonable assistance shall include transfer of all processes, procedures,
know-how and data necessary or useful to process the Product and to Produce the Product in accordance with the Product Specifications (as in effect at the time of such termination or expiration) and FDA
guidelines, including assistance of Catalent personnel in compiling and transferring this information. Such reasonable assistance will be provided by Catalent at its customary per/hour, per/person rates then in effect relative to the work to be
performed. 

  

	 	10.5.	 Accrued Rights; Surviving Obligations. 

 

	 	10.5.1	 Accrued Rights. Termination or expiration of this Agreement for any reason shall be without prejudice to
any rights that shall have accrued to the benefit of either Party prior to such termination or expiration. Such termination or expiration shall not relieve either Party from obligations that are expressly indicated to survive termination or
expiration of this Agreement. 

  

	 	10.5.2	 Surviving Obligations. All of the Parties’ respective rights and obligations under Sections 1
(“Definitions”), 2.3 (“License Grant”) (for the period set forth therein, and subject to the terms set forth therein), 2.5 (“Ownership and Risk of Loss”), 3.6 (“No Amendment of Agreement”),
3.8 (“Cancellation of Firm Order”), 3.9.1 (“Client-Supplied Component Storage”), 3.12 (“Audit”), 3.13.3 (“Ownership and Risk of Loss; Disposition of Equipment”), 4 (“Nonconforming Product”),
5.1 (“Product Price”), 5.2 (“Cost Reimbursement”), 5.3 (“Payment Terms”), 5.6 (“Insurance”), 6 (“Representations and Warranties”), 7 (“Indemnification; Limitation of Liability; Waiver
of Subrogation”), 8 (“Confidentiality and Non-Solicitation of 

  

			
	CONFIDENTIAL INFORMATION	  	Page 36 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	
Employees”), 9 (“Intellectual Property”), 10.4 (“Consequences of Termination”), 10.5 (“Accrued Rights; Surviving Obligations”), 11.7
(“Records”), 11.9 (“Ownership of Regulatory Filings”), 12.2 (“Severability”), 12.3 (“Notices”), 12.4 (“Governing Law”), 12.5 (“Alternative Dispute Resolution”),
12.6 (“Entire Agreement”), 12.7 (“Attempts to Amicably Resolve Disputes”), 12.8 (“Waiver”), 12.9 (“Independent Contractors”), and 12.17 (“Quality Agreement”) shall survive termination or
expiration of this Agreement. 

  

	11.	 Regulatory. 

  

	 	11.1.	 Permits. Each Party shall be responsible, at its own expense, to obtain and maintain all permits and
licenses required for it to carry out its obligations hereunder. 

  

	 	11.2.	 Regulatory Approvals. Client will diligently pursue Regulatory Approval of marketing licenses for each
Product Produced by Catalent hereunder. Client will advise Catalent of document requirements in support of NDA and/or BLA and similar applications required of foreign governments and agencies including amendments, license applications, supplements
and maintenance of such. Catalent will provide documents and assist Client in preparation of submissions to Regulatory Authorities (both U.S. and foreign) designated by Client in support of Client’s NDAs (if any), and similar applications
required of foreign governments and licenses. All regulatory submission preparation and maintenance performed by Catalent for Client shall be specified in a Project Plan for regulatory services. 

 

	 	11.3.	 Compliance with CGMPs; Monitoring of Records. Catalent shall monitor and maintain reasonable records
respecting its compliance with CGMPs in the manner provided by the Quality Agreement, including the process of establishment and implementation of the operating procedures and the training of personnel as are reasonably necessary to assure such
compliance. 

  

	 	11.4.	 Regulatory Authority Inspections. At Client’s request, Catalent will authorize Regulatory
Authorities to review related applications on Client’s behalf. Catalent will notify Client within [***] calendar days of all contacts with Regulatory Authorities (both written and verbal) related to each Product. Catalent shall inform Client of
the result of any regulatory inspection which directly affects the Production of a Product, including any notice of inspection, notice of violation or other similar notice received by Catalent affecting Production, Facility, testing, storage or
handling of a Product. In the event of an FDA inspection which directly involves a Product, Client shall be 

  

			
	CONFIDENTIAL INFORMATION	  	Page 37 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	
immediately informed of the issuance of the Notice of Inspection (FDA Form 482). In the event that there are inspectional observations (FDA Form 483), Client shall be informed immediately and
shall have the opportunity to review and provide Catalent with comments to Catalent’s response. Client shall provide its comments to the response of these observations within [***] business days. The contents of Catalent’s response shall
be determined by Catalent in its sole discretion. 

  

	 	11.5.	 Regulatory Communications and Correspondence. Except as provided in Section 11.4 (“Regulatory
Authority Inspections”), any and all other communications from and to the FDA or other Regulatory Authorities related to the Production of the Product at the Facility shall be handled in accordance with the terms and conditions of the Quality
Agreement, or as otherwise agreed in writing by Catalent and Client. 

  

	 	11.6.	 Regulatory Filings and Maintenance. Client shall be solely responsible for preparing and submitting to
the FDA all documents necessary for the Regulatory Approval of Product including adverse drug experience reports, field alert reports, periodic reports and applications for renewals, variations, supplements and amendments. Catalent shall prepare and
maintain all manufacturing files, certificates, authorizations, data and other records that directly pertain to the Production of the Product, as further set forth in the Quality Agreement or as otherwise agreed in writing by Catalent and Client.

  

	 	11.7.	 Records. Catalent shall maintain the records required by the terms and conditions of the Quality
Agreement, or as otherwise agreed to in writing by Catalent and Client in a Project Plan. Catalent agrees that, in response to any complaint, or in the defense by Client of any litigation, hearing, regulatory proceeding or investigation relating to
the manufacture of Product, Catalent shall use [***] efforts to make available to Client (during normal business hours and upon reasonable prior written notice) such Catalent employees and records as may be reasonably necessary to permit the
effective response to, defense of, or investigation of such matters, subject to appropriate confidentiality protections. Client shall reimburse Catalent for all costs and expenses incurred by Catalent in connection with the performance of
Catalent’s obligations under the immediately preceding sentence. 

  

	 	11.8.	 Notification. Each Party shall promptly notify the other of new regulatory requirements of which it
becomes aware that are relevant to the Production of a Product under this Agreement and that are required by the FDA, any other applicable Regulatory Authority or other Applicable Laws or governmental regulations. The Parties shall confer with each
other with respect to the best means to comply with such requirements. 

  

			
	CONFIDENTIAL INFORMATION	  	Page 38 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	11.9.	 Ownership of Regulatory Filings. Client shall be the sole owner of all regulatory filings and all
governmental approvals obtained by Client from any Regulatory Authority with respect to the Product. Notwithstanding the foregoing, and for the avoidance of doubt, all rights in and to Catalent Intellectual Property Rights and Catalent Confidential
Information shall remain entirely vested in Catalent. 

  

	12.	 Miscellaneous. 

 

	 	12.1.	 Assignment. Neither Party may assign this Agreement without the prior written consent of the
other Party, which consent will not be unreasonably withheld. Notwithstanding the foregoing, either Party may, without the prior consent of the other Party, assign this Agreement to the successor entity in connection with a merger or acquisition, or
to an entity acquiring substantially all of the product line or business operations of the assigning Party to which this Agreement pertains, provided that such successor or acquiring entity will expressly assume in writing the obligation to perform
in accordance with the terms and conditions of this Agreement. Any purported assignment not in compliance with this Section 12.1 (“Assignment”) shall be void. 

 

	 	12.2.	 Severability. If any item or provision of this Agreement shall to any extent be invalid or
unenforceable, it shall be severed from this Agreement, and the remainder of this Agreement shall not be affected thereby, and each term and provision of this Agreement shall be valid and shall be enforced to the fullest extent permitted by
Applicable Law. 

  

	 	12.3.	 Notices. All notices and other communications under this Agreement shall be in writing and shall
be deemed given: (A) when delivered personally or by hand; (B) when delivered by electronic mail (e-mail); (C) when received or refused, if sent by registered or certified mail (return receipt
requested), postage prepaid; or (D) when delivered, if sent by express courier service; in each case to the parties at the following addresses (or at such other address for a party as shall be specified by like notice; provided, that notices of
a change of address shall be effective only upon receipt thereof): 

 If to Catalent Bloomington: 

Catalent Indiana, LLC 

1300 South Patterson Drive 

Bloomington, Indiana 47403 

Attention: [***] 

E-Mail: [***] 

  

			
	CONFIDENTIAL INFORMATION	  	Page 39 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

 With a copy to: 

Catalent Pharma Solutions, LLC 

14 Schoolhouse Road 

Somerset, NJ 08873 

Attention: [***] 

E-Mail: [***] 

If to Client: Catalyst Biosciences, Inc. 

611 Gateway Boulevard, Suite 710 

South San Francisco, CA 94080 

Attention: [***] 
  

	 	12.4.	 Governing Law. The Agreement shall be governed by and construed in accordance with the laws of
the state of New York, without regard for its conflict of laws principles. 

  

	 	12.5.	 Alternative Dispute Resolution. Any dispute arising between the Parties in connection with this
Agreement shall first be presented to the respective senior executives of the Parties for their consideration and resolution as set forth in Section 12.7 (“Attempts to Amicably Resolve Disputes”) below. If such Parties’
executives cannot resolve such dispute within [***] days, then such dispute may be submitted by either Party to arbitration by the International Institute for Conflict Prevention and Resolution, 30 E. 33rd Street, 6th Floor, New York, NY 10016
(“CPR”) by one arbitrator selected by the Parties. If no agreement on an arbitrator can be reached within [***] days after the CPR offers names of potential arbitrators, then the CPR will choose one arbitrator having reasonable experience
in commercial transactions of the type described in this Agreement. The arbitration shall take place in the English language in New York City, New York, in accordance with the CPR administered arbitration rules then in effect, and judgment upon any
award rendered in such arbitration will be binding and may be entered in any court having jurisdiction of the matter. The arbitration shall commence within [***] days of the date on which an arbitrator is selected. The arbitrator’s decision
shall set forth a reasoned basis for any award of damages or finding of liability. The arbitrator shall not have power to award damages in excess of actual compensatory damages and shall not multiply actual damages or award punitive damages. The
arbitrator shall award to the prevailing party, if any, its costs and attorneys’ fees and expenses reasonably incurred in connection with the arbitration. 

 

	 	12.6.	 Entire Agreement. This Agreement constitutes the entire and exclusive agreement between the
Parties with respect to the subject matter hereof and supersedes and cancels all previous discussions, agreements, representations, commitments and writing in respect thereof. No amendment or addition to this

  

			
	CONFIDENTIAL INFORMATION	  	Page 40 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	
Agreement shall be effective unless reduced to writing and executed by the authorized representatives of the Parties. In the event of a conflict between the provisions of this Agreement and the
provisions of any exhibits or attachments hereto, including any Project Plan, the provisions of this Agreement shall govern. 

  

	 	12.7.	 Attempts to Amicably Resolve Disputes. 

 

	 	12.7.1	 To avoid litigation and to resolve any conflicts that arise during the performance of the Services or
thereafter, Catalent and Client agree that, prior to the commencement of arbitration by either Party, the Parties shall engage in executive mediation. Either Party may seek executive mediation by delivering a written request for such mediation to
the other. Delivery of such request may be made by hand or by electronic mail. The request shall be addressed in accordance with Section 12.3 (“Notices”). 

 

	 	12.7.2	 Within [***] business days of the delivery of such request, each Party shall appoint a company executive
who is not directly involved in the dispute to meet with the other Party’s company executive for the purpose of resolving the dispute. No later than [***] business days from their appointment, the two executives shall meet to consider the
dispute. They may request such information as either deems necessary and may meet jointly or separately with the party representatives involved in the dispute. The two appointed executives shall use [***] efforts to reach a resolution of the
dispute. 

  

	 	12.7.3	 If a resolution is reached, it shall be reduced to writing and shall be final and binding on the
Parties. 

  

	 	12.7.4	 If the two executives cannot reach agreement within [***] business days of their initial meeting, unless
the two executives agree to additional review time, either Party may thereafter pursue any remedy at law or in equity. 

  

	 	12.8.	 Waiver. No waiver of any rights shall be effective unless consented to in writing by the Party to
be charged and the waiver of any breach or default shall not constitute a waiver of any other right hereunder or any subsequent breach or default. 

  

			
	CONFIDENTIAL INFORMATION	  	Page 41 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	12.9.	 Independent Contractors. Catalent and Client each acknowledge that they shall be independent
contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture, agency or any type of fiduciary relationship. Neither Catalent nor Client shall have the authority to make any statements,
representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior consent of the other Party to do so. 

 

	 	12.10.	 Affiliate(s). Any licenses granted under this Agreement by Client will be deemed to be granted both to
Catalent and Catalent’s Affiliate(s). Catalent shall cause its Affiliate(s) involved in the provision of the Services to comply fully with the provisions of this Agreement as though such Affiliate(s) were expressly named as joint obligors
hereunder. 

  

	 	12.11.	 Counterparts/Facsimile. This Agreement may be executed in two or more counterparts, each of which shall
be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile signatures shall have the same force and effect as original signatures. 

 

	 	12.12.	 Subcontracting. Catalent may subcontract the performance of the Services to qualified third
parties only with Client’s prior written consent (“Permitted Subcontractors”) and provided that (a) Catalent notifies Client of the proposed Permitted Subcontractor and identifies the specific Services to be performed by
the proposed Permitted Subcontractor, (b) Client provides written approval, such approval not to be unreasonably withheld, and (c) Catalent ensures the Permitted Subcontractor performs those Services in a manner consistent with the terms
and conditions of this Agreement. Catalent shall be responsible for all acts and omissions of its Permitted Subcontractors. 

  

	 	12.13.	 Force Majeure. Neither Party shall be liable for failure to perform its obligations under this Agreement
(or for a delay in the performance of such obligations), and neither shall be deemed in breach of its obligations, if such failure or delay is due to Force Majeure. In event of Force Majeure, the Party affected thereby shall use [***] efforts to
cure or overcome the same and resume performance of its obligations hereunder. If an event of Force Majeure continues and causes a Party to delay its performance of its obligations for more than [***] days, then the other Party shall have the right
upon written notice to terminate this Agreement without any liability to the other Party. 

  

	 	12.14.	 Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by one Party to the
other are, for all purposes of Section 365(n) of Title XI of the United States Code (“Title XI”), licenses of rights to “intellectual property” as defined in Title XI. If a Party seeks or involuntarily is placed under
Title XI and the trustee rejects this Agreement as contemplated under 11 U.S.C. 365(n)(1), the other Party hereby elects, pursuant to Section 365(n) of Title XI, to retain all rights granted to it under this Agreement to the extent permitted by
Applicable Law. 

  

			
	CONFIDENTIAL INFORMATION	  	Page 42 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

	 	12.15.	 Exporter of Record. Catalent shall be the exporter of record for any Product shipped out of the
United States. Catalent warrants that all shipments of Product exported from the United States will be made in compliance with all export laws and regulations and all applicable import laws and regulations of the country of importation. Catalent
shall be responsible for obtaining any licenses or government authorization(s) necessary for the exportation of Product from the United States, and for ensuring that all domestic and international shipments of Product are made in accordance with all
applicable laws and regulations, including but not limited to Department of Transportation and Department of Homeland Security regulations related to transportation of biological agents. Catalent’s designated carrier and freight forwarder shall
solely be Catalent’s agent and shall solely be responsible for preparing and filing any relevant declarations or other documents required for the export. Client shall bear all costs and expenses associated with this Section 12.15
(“Exporter of Record”). 

  

	 	12.16.	 Importer of Record. In the event any material or equipment to be supplied by Client, including without
limitation Client-Supplied Components and Bulk Drug Substance, is imported into the United States for delivery to Catalent (“Imported Goods”), such Imported Goods shall be imported DDP Facility (Incoterms 2010). Catalent
shall be deemed to be the “Importer of Record” of such Imported Goods. As the Importer of Record, Catalent shall be responsible for all aspects of the Imported Goods including, without limitation (a) payment of all tariffs, duties,
customs, fees, expenses and charges payable in connection with the importation and delivery of the Imported Goods, and (b) keeping all records, documents, correspondence and tracking information required by applicable laws, rules and
regulations arising out of or in connection with the importation or delivery of the Imported Goods. Client shall reimburse Catalent for (a). 

  

	 	12.17.	 Quality Agreement. The safety, quality control, and quality assurance aspects of the Services
shall be pursuant to the Quality Agreement. In the event of a conflict between the provisions of this Agreement and the provisions of the Quality Agreement, the provisions of this Agreement shall govern. 

 

	 	12.18.	 Counterparts. This Agreement may be executed in one or more counterparts, each of which will be deemed
an original but all of which together will constitute one and the same instrument. Any photocopy, facsimile or electronic reproduction of the executed Agreement shall constitute an original. 

  

			
	CONFIDENTIAL INFORMATION	  	Page 43 of 44

 Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit
because it is both not material and would be competitively harmful if publicly disclosed. 
  

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be signed by their duly
authorized representatives to be effective as of the Effective Date. 
  

											
	Catalent Indiana, LLC	 		 		 	Catalyst Biosciences, Inc.
						
	By:	 	 [***]
	 	            	 	    	 	By:	 	 /s/ Nassim Usman

	Name: [***]	 		 		 	Name: Nassim Usman, Ph.D.
	Title: [***]	 		 		 	Title: President & CEO

  

			
	CONFIDENTIAL INFORMATION	  	Page 44 of 44EX-4.1

 Exhibit 4.1 

Execution Version 

REGISTRATION RIGHTS AGREEMENT 

THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October 14, 2019, is by and among Parsley Energy,
Inc., a Delaware corporation (the “Company”), Q-Jagged Peak Energy Investment Partners, LLC, a Delaware limited liability company (the “Initial Holder”), and the other Holders
from time to time parties hereto. 
 RECITALS: 

WHEREAS, this Agreement is being entered into pursuant to the Agreement and Plan of Merger dated as of October 14, 2019, among the
Company, Jackal Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of the Company, and Jagged Peak Energy Inc., a Delaware corporation (the “Merger Agreement”); and 

WHEREAS, upon consummation of the transactions contemplated by the Merger Agreement, the Company will issue to the Initial Holder the
Class A Shares (as defined below) in accordance with the terms of the Merger Agreement. 
 WHEREAS, this Agreement shall become
effective as of the Effective Time (as defined below). 
 NOW THEREFORE, in consideration of the mutual covenants and agreements set forth
herein and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by each party hereto, the parties hereby agree as follows: 

ARTICLE I 
 DEFINITIONS

 As used herein, the following terms shall have the following respective meanings: 

“Adoption Agreement” means an Adoption Agreement in the form attached hereto as Exhibit A. 

“Affiliate” means (a) as to any Person, other than an individual Holder, any other Person who directly, or indirectly
through one or more intermediaries, controls, is controlled by or is under common control with such Person and (b) as to any individual, (i) any Relative of such individual, (ii) any trust whose primary beneficiaries are one or more
of such individual and such individual’s Relatives, (iii) the legal representative or guardian of such individual or any of such individual’s Relatives if one has been appointed and (iv) any Person controlled by one or more of
such individual or any Person referred to in clauses (i), (ii) or (iii) above. As used in this Agreement, the term “control,” including the correlative terms “controlling,” “controlled by” and “under common
control with,” means possession, directly or indirectly, of the power to direct or cause the direction of management or policies (whether through ownership of securities or any partnership or other ownership interest, by contract or otherwise)
of a Person. For the avoidance of doubt, for purposes of this Agreement, (a) (i) the Company, on the one hand, and the Holders, on the other hand, shall not be considered Affiliates and (ii) any fund, entity or account managed, advised or sub-advised, directly or indirectly, by a Holder or any of its Affiliates, shall be considered an Affiliate of such Holder and (b) with respect to any fund, entity or account managed, advised or

 
sub-advised directly or indirectly, by any Holder or any of its Affiliates, the direct or indirect equity owners thereof, including limited partners of any
Holder or any Affiliate thereof, shall be considered an Affiliate of such Holder. 
 “Agreement” has the meaning set forth
in the introductory paragraph. 
 “Board” means the board of directors of the Company. 

“Business Day” means any day other than a Saturday, Sunday, any federal holiday or any other day on which banking
institutions in the State of Texas or the State of New York are authorized or required to be closed by law or governmental action. 

“Class A Common Stock” means the Class A common stock of the Company, par value $0.01 per share. 

“Class A Shares” means the number of shares of Class A Common Stock issuable to the Initial Holder
pursuant to the terms of the Merger Agreement. 
 “Commission” means the Securities and Exchange Commission or any
successor governmental agency. 
 “Company” has the meaning set forth in the introductory paragraph. 

“Company Securities” has the meaning set forth in Section 2.4(c)(i). 

“DE Registration Rights Agreement” has the meaning set forth in Section 2.10. 

“Effective Time” has the meaning assigned such term in the Merger Agreement. 

“Effectiveness Period” has the meaning set forth in Section 2.1(c). 

“Exchange Act” means the Securities Exchange Act of 1934, as amended, or any successor federal statute, and the rules and
regulations of the Commission thereunder, all as the same shall be in effect at the time. 
 “Holder” means any record
holder of Registrable Securities. 
 “Indemnified Party” has the meaning set forth in
Section 3.3. 
 “Indemnifying Party” has the meaning set forth in
Section 3.3. 
 “Losses” has the meaning set forth in Section 3.1. 

“Majority Holders” shall mean, at any time, the Holder or Holders of more than fifty percent (50%) of the Registrable
Securities at such time 
 “Managing Underwriter” means, with respect to any Underwritten Offering, the lead book-running
manager(s) of such Underwritten Offering. 

  
 2 

 “Merger Agreement” has the meaning set forth in the recitals. 

“Minimum Number of Registrable Securities” means 1,000,000 Registrable Securities; provided, however, that such number
of Registrable Securities shall be appropriately adjusted in connection with any event described in Section 6.5. 

“Permitted Transferee” means any Affiliate of a Holder, provided that such Transferee has delivered to the Company a duly
executed Adoption Agreement. 
 “Person” means any individual, corporation, partnership, limited liability company, firm,
association, trust, government, governmental agency or other entity, whether acting in an individual, fiduciary or other capacity. 

“Piggybacking Holder” has the meaning set forth in Section 2.4(a). 

“Piggyback Underwritten Offering” has the meaning set forth in Section 2.4(a). 

“Proceeding” shall mean an action, claim, suit, arbitration or proceeding (including, without limitation, an investigation or
partial proceeding, such as a deposition), whether commenced or threatened. 
 “Registrable Securities” shall mean
(a) the Class A Shares and (b) any securities issued or issuable with respect to the Class A Shares by way of distribution or in connection with any reorganization or other recapitalization, merger, consolidation or otherwise;
provided, however, that a Registrable Security shall cease to be a Registrable Security when (i) such Registrable Security has been disposed of pursuant to an effective Registration Statement, (ii) such Registrable Security is
disposed of under Rule 144 under the Securities Act or any other exemption from the registration requirements of the Securities Act as a result of which the Transferee thereof does not receive “restricted securities” as defined in Rule 144
under the Securities Act, or (iii) such Registrable Security has been sold or disposed of in a transaction in which the Transferor’s rights under this Agreement are not assigned to the Transferee pursuant to Article V; and
provided, further, that any security that has ceased to be a Registrable Security shall not thereafter become a Registrable Security and any security that is issued or distributed in respect of securities that have ceased to be Registrable
Securities shall not be a Registrable Security. 
 “Registration Expenses” means all expenses incurred by the Company in
complying with Article II, including, without limitation, all registration and filing fees, printing expenses, road show expenses, fees and disbursements of counsel and independent public accountants and independent petroleum engineers for
the Company, fees and expenses (including counsel fees) incurred in connection with complying with state securities or “blue sky” laws, fees of the Financial Industry Regulatory Authority, Inc., and fees of transfer agents and
registrars, but excluding any Selling Expenses. 
 “Registration Statement” means any registration statement of the Company
filed or to be filed with the Commission under the Securities Act, including the related prospectus, amendments and supplements to such registration statement, and including pre- and post-effective amendments,
and all exhibits and all material incorporated by reference in such registration statement. 

  
 3 

 “Relative” means, with respect to any natural person: (a) such natural
person’s spouse, (b) any lineal descendant, parent, grandparent, great grandparent or sibling or any lineal descendant of such sibling (in each case whether by blood or legal adoption), and (c) the spouse of a natural person described
in clause (b) of this definition. 
 “Requesting Holder” has the meaning set forth in
Section 2.2(a). 
 “Requesting Holder Securities” has the meaning set forth in
Section 2.2(c)(i). 
 “Section 2.2 Maximum Number of Shares” has the meaning
set forth in Section 2.2(c). 
 “Section 2.4 Maximum Number of Shares” has the
meaning set forth in Section 2.4(c). 
 “Securities Act” means the Securities Act of 1933, as
amended, or any successor federal statute, and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. References to any rule under the Securities Act shall be deemed to refer to any similar or
successor rule or regulation. 
 “Selling Expenses” means all (a) underwriting fees, discounts and selling commissions
allocable to the sale of Registrable Securities, (b) transfer taxes allocable to the sale of the Registrable Securities, (c) costs or expenses related to any roadshows conducted in connection with the marketing of any Shelf Underwritten
Offering, and (d) fees and expenses of counsel engaged by any Holders (subject to Article III). 
 “Selling
Holder” means a Holder selling Registrable Securities pursuant to a Registration Statement. 
 “Shelf Piggybacking
Holder” has the meaning set forth in Section 2.2(b). 
 “Shelf Registration Statement”
has the meaning set forth in Section 2.1(a). 
 “Shelf Underwritten Offering” has the meaning set
forth in Section 2.2(a). 
 “Shelf Underwritten Offering Request” has the meaning set forth in
Section 2.2(a). 
 “Suspension Period” has the meaning set forth in
Section 2.3. 
 “Transfer” means any offer, sale, pledge, encumbrance, hypothecation, entry into
any contract to sell, grant of an option to purchase, short sale, assignment, transfer, exchange, gift, bequest or other disposition, direct or indirect, in whole or in part, by operation of law or otherwise. “Transfer,” when used
as a verb, and “Transferee” and “Transferor” have correlative meanings. 
 “Underwritten
Offering” means an offering (including an offering pursuant to a Shelf Registration Statement) in which shares of Class A Common Stock are sold to an underwriter on a firm commitment basis for reoffering to the public. 

  
 4 

 “Underwritten Offering Filing” means (a) with respect to a Shelf
Underwritten Offering, a preliminary prospectus supplement (or prospectus supplement if no preliminary prospectus supplement is used) to the Shelf Registration Statement relating to such Shelf Underwritten Offering, and (b) with respect to a
Piggyback Underwritten Offering, (i) a preliminary prospectus supplement (or prospectus supplement if no preliminary prospectus supplement is used) to an effective shelf Registration Statement (other than the Shelf Registration Statement) in
which Registrable Securities could be included and Holders could be named as selling security holders without the filing of a post-effective amendment thereto (other than a post-effective amendment that becomes effective upon filing) or (ii) a
Registration Statement (other than the Shelf Registration Statement), in each case relating to such Piggyback Underwritten Offering. 

“WKSI” means a well-known seasoned issuer (as defined in Rule 405 under the Securities Act). 

ARTICLE II 

REGISTRATION RIGHTS 

Section 2.1    Shelf Registration. 

(a)    As soon as practicable after the date of this Agreement, and in any event within 10 Business Days, the Company shall
prepare and file a “shelf” registration statement under the Securities Act to permit the resale of the Registrable Securities from time to time as permitted by Rule 415 under the Securities Act (or any similar provision adopted by the SEC
then in effect) (the “Shelf Registration Statement”), and the Company shall use commercially reasonable efforts to cause such Registration Statement to become or be declared effective as soon as practicable after the filing thereof,
including by filing an automatic shelf registration statement that becomes effective upon filing with the Commission in accordance with Rule 462(e) under the Securities Act to the extent the Company is then a WKSI. Following the effective date of
the Shelf Registration Statement, the Company shall notify the Holders of the effectiveness of such Registration Statement. 

(b)    The Shelf Registration Statement shall be on Form S-3 or, if Form S-3 is not then available to the Corporation, on Form S-1 or such other form of registration statement as is then available to effect a registration for resale of such
Registrable Securities and shall contain a prospectus in such form as to permit any Holder to sell such Registrable Securities pursuant to Rule 415 under the Securities Act (or any successor or similar rule adopted by the Commission then in effect)
at any time beginning on the effective date for such Registration Statement. The Shelf Registration Statement shall provide for the distribution or resale pursuant to any method or combination of methods legally available to the Holders and
requested by the Majority Holders. 
 (c)    The Company shall use commercially reasonable efforts to cause the Shelf
Registration Statement to remain effective, and to be supplemented and amended to the extent necessary to ensure that the Shelf Registration Statement is available or, if not available, that another Registration Statement is available, for the
resale of all the Registrable Securities until all of the Registrable Securities have ceased to be Registrable Securities or the earlier termination of this Agreement (as to all Holders) pursuant to Section 6.1 (the
“Effectiveness Period”). 

  
 5 

 (d)    When effective, the Shelf Registration Statement (including the
documents incorporated therein by reference) will comply as to form in all material respects with all applicable requirements of the Securities Act and the Exchange Act and will not contain an untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary to make the statements therein not misleading (in the case of any prospectus contained in the Shelf Registration Statement, in the light of the circumstances under which such statements are
made). 
 Section 2.2    Underwritten Shelf Offering Requests. 

(a)    In the event that any Holder or group of Holders elects to dispose of Registrable Securities under a Registration
Statement pursuant to an Underwritten Offering and reasonably expects gross proceeds of at least $150 million from such Underwritten Offering (including proceeds attributable to any Registrable Securities included in such Underwritten Offering
by any Shelf Piggybacking Holders), the Company shall, at the request (a “Shelf Underwritten Offering Request”) of such Holder or Holders (in such capacity, a “Requesting Holder”), enter into an underwriting
agreement in a form as is customary in Underwritten Offerings of securities by the Company with the underwriter or underwriters selected pursuant to Section 2.2(d) and shall take all such other reasonable actions as are
requested by the Managing Underwriter of such Underwritten Offering and/or the Requesting Holders in order to expedite or facilitate the disposition of such Registrable Securities and, subject to Section 2.2(c), the
Registrable Securities requested to be included by any Shelf Piggybacking Holder (a “Shelf Underwritten Offering”); provided, however, that the Company shall have no obligation to facilitate or participate in more than two
Shelf Underwritten Offerings that are initiated by a Holder pursuant to this Section 2.2 during any 12-month period (and no more than one Shelf Underwritten Offering in any 90-day
period). 
 (b)    If the Company receives a Shelf Underwritten Offering Request, it will give written notice of such
proposed Shelf Underwritten Offering to each Holder (other than the Requesting Holder) that, together with such Holder’s Affiliates, holds at least the Minimum Number of Registrable Securities, which notice shall be held in strict confidence by
such Holders and shall include the anticipated filing date of the related Underwritten Offering Filing and, if known, the number of shares of Class A Common Stock that are proposed to be included in such Shelf Underwritten Offering, and of such
Holders’ rights under this Section 2.2(b). Such notice shall be given promptly (and in any event at least five Business Days before the filing of the Underwritten Offering Filing or two Business Days before the filing
of the Underwritten Offering Filing in connection with a bought or overnight Underwritten Offering); provided, that if the Shelf Underwritten Offering is a bought or overnight Underwritten Offering and the Managing Underwriter advises the
Company and the Requesting Holder that the giving of notice pursuant to this Section 2.2(b) would adversely affect the offering, no such notice shall be required (and such Holders shall have no right to include Registrable
Securities in such bought or overnight Underwritten Offering); and provided further, that the Company shall not so notify any such other Holder that has notified the Company (and not revoked such notice) requesting that such Holder not
receive notice from the Company of any proposed Shelf Underwritten Offering. If such notice is delivered pursuant to this Section 2.2(b), each such Holder shall then have four Business Days (or one Business Day in the case
of a bought or overnight Underwritten Offering) after the date on which the Holders received notice pursuant to this Section 2.2(b) to request inclusion of Registrable Securities in the Shelf Underwritten Offering (which
request shall specify the maximum number of Registrable Securities intended to be disposed of by such Holder and such other information as is reasonably required to effect the inclusion of such Registrable Securities)

  
 6 

 
(any such Holder making such request, a “Shelf Piggybacking Holder”). If no request for inclusion from a Holder is received within such period, such Holder shall have no further
right to participate in such Shelf Underwritten Offering. 
 (c)    If the Managing Underwriter of the Shelf
Underwritten Offering shall inform the Company and the Requesting Holders in writing, with a copy to be provided upon request to any Shelf Piggybacking Holder, of its belief that the number of Registrable Securities requested to be included in such
Shelf Underwritten Offering by the Shelf Piggybacking Holders (and any other shares of Class A Common Stock requested to be included by any other Persons having registration rights with respect to such offering), when added to the number of
Registrable Securities proposed to be offered by the Requesting Holders, would materially adversely affect such offering, then the Company shall include in the applicable Underwritten Offering Filing, to the extent of the total number of Registrable
Securities that the Company is so advised can be sold in such Shelf Underwritten Offering without so materially adversely affecting such offering (the “Section 2.2 Maximum Number of Shares”), Registrable
Securities in the following priority: 
 (i)    First, all Registrable Securities that the Requesting Holder and Shelf
Piggybacking Holders requested to be included therein (the “Requesting Holder and Shelf Piggybacking Holders Securities”) (pro rata among the Requesting Holders and Shelf Piggybacking Holders based on the number of
Registrable Securities each requested to be included), and 
 (ii)    Second, to the extent that the number of
Requesting Holder and Shelf Piggybacking Holders Securities is less than the Section 2.2 Maximum Number of Shares, the shares of Class A Common Stock requested to be included by any other Persons having registration rights with respect to
such offering, pro rata among such other Persons based on the number of Class A Common Stock each requested to be included. 

(d)    The Company shall propose three or more nationally prominent firms of investment bankers reasonably acceptable to
the Company and the Initial Holder to act as the Managing Underwriter or as other underwriters in connection with such Shelf Underwritten Offering from which the holders of more than 50% of the Registrable Securities to be so offered shall select
the Managing Underwriter and the other underwriters. The Requesting Holders shall determine the pricing of the Registrable Securities offered pursuant to any Shelf Underwritten Offering and the applicable underwriting discounts and commissions and
determine the timing of any such Shelf Underwritten Offering, subject to Section 2.3. 

Section 2.3    Delay and Suspension Rights. Notwithstanding any other provision of
this Agreement, the Company may (i) delay filing or effectiveness of a Shelf Registration Statement (or any amendment thereto) or effecting a Shelf Underwritten Offering or (ii) suspend the Holders’ use of any prospectus that is a
part of a Shelf Registration Statement upon written notice to each Holder whose Registrable Securities are included in such Shelf Registration Statement (provided that in no event shall such notice contain any material
non-public information regarding the Company) (in which event such Holder shall discontinue sales of Registrable Securities pursuant to such Registration Statement but may settle any then-contracted sales of
Registrable Securities), in each case for a period of up to 60 consecutive days, if the Board determines (A) that such delay or suspension is in the best interest of the Company and its stockholders generally due to a pending

  
 7 

 
financing or other transaction involving the Company, including a proposed sale of Class A Common Stock pursuant to a Company Registration Statement, (B) that such registration or
offering would render the Company unable to comply with applicable securities laws or (C) that such registration offering would require disclosure of material information that the Company has a bona fide business purpose for preserving
as confidential (any such period, a “Suspension Period”); provided, however, that in no event shall any Suspension Periods collectively exceed an aggregate of 120 days in any 12-month
period. 
 Section 2.4    Piggyback Registration Rights. 

(a)    Subject to Section 2.4(c), if the Company at any time proposes to file an Underwritten
Offering Filing for an Underwritten Offering of shares of Class A Common Stock for its own account or for the account of any other Persons who have or have been granted registration rights (a “Piggyback Underwritten Offering”),
it will give written notice of such Piggyback Underwritten Offering to each Holder that, together with such Holder’s Affiliates, holds at least the Minimum Number of Registrable Securities, which notice shall be held in strict confidence by
such Holders and shall include the anticipated filing date of the Underwritten Offering Filing and, if known, the number of shares of Class A Common Stock that are proposed to be included in such Piggyback Underwritten Offering, and of such
Holders’ rights under this Section 2.4(a). Such notice shall be given promptly (and in any event at least five Business Days before the filing of the Underwritten Offering Filing or two Business Days before the filing
of the Underwritten Offering Filing in connection with a bought or overnight Underwritten Offering); provided, that if the Piggyback Underwritten Offering is a bought or overnight Underwritten Offering and the Managing Underwriter advises the
Company that the giving of notice pursuant to this Section 2.4(a) would adversely affect the offering, no such notice shall be required (and such Holders shall have no right to include Registrable Securities in such bought
or overnight Underwritten Offering). If such notice is delivered to pursuant to this Section 2.4(a), each such Holder shall then have four Business Days (or one Business Day in the case of a bought or overnight Underwritten
Offering) after the date on which the Holders received notice pursuant to this Section 2.4(a) to request inclusion of Registrable Securities in the Piggyback Underwritten Offering (which request shall specify the maximum
number of Registrable Securities intended to be disposed of by such Holder and such other information as is reasonably required to effect the inclusion of such Registrable Securities) (any such Holder making such request, a “Piggybacking
Holder”). If no request for inclusion from a Holder is received within such period, such Holder shall have no further right to participate in such Piggyback Underwritten Offering. Subject to Section 2.4(c), the
Company shall use its commercially reasonable efforts to include in the Piggyback Underwritten Offering all Registrable Securities that the Company has been so requested to include by the Piggybacking Holders; provided, however, that if, at
any time after giving written notice of a proposed Piggyback Underwritten Offering pursuant to this Section 2.4(a) and prior to the execution of an underwriting agreement with respect thereto, the Company or such other
Persons who have or have been granted registration rights, as applicable, shall determine for any reason not to proceed with or to delay such Piggyback Underwritten Offering, the Company shall give written notice of such determination to the
Piggybacking Holders (which such Holders will hold in strict confidence) and (i) in the case of a determination not to proceed, shall be relieved of its obligation to include any Registrable Securities in such Piggyback Underwritten Offering
(but not from any obligation of the Company to pay the Registration Expenses in connection therewith), and (ii) in the case of a determination to delay, shall be 

  
 8 

 
permitted to delay inclusion of any Registrable Securities for the same period as the delay in including the shares of Class A Common Stock to be sold for the Company’s account or for
the account of such other Persons who have or have been granted registration rights, as applicable. 
 (b)    Each
Holder shall have the right to withdraw its request for inclusion of its Registrable Securities in any Piggyback Underwritten Offering at any time prior to the execution of an underwriting agreement with respect thereto by giving written notice to
the Company of its request to withdraw. Any Holder may deliver written notice (an “Opt-Out Notice”) to the Company requesting that such Holder not receive notice from the Company of any
proposed Piggyback Underwritten Offering; provided, however, that such Holder may later revoke any such Opt-Out Notice in writing. Following receipt of an Opt-Out
Notice from a Holder (unless subsequently revoked), the Company shall not, and shall not be required to, deliver any notice to such Holder pursuant to this Section 2.4 and such Holder shall no longer be entitled to
participate in any Piggyback Underwritten Offering. 
 (c)    If the Managing Underwriter of the Piggyback Underwritten
Offering shall inform the Company, of its belief that the number of Registrable Securities requested to be included in such Piggyback Underwritten Offering, when added to the number of shares of Class A Common Stock proposed to be offered by
the Company or such other Persons who have or have been granted registration rights (and any other shares of Class A Common Stock requested to be included by any other Persons having registration rights on parity with the Piggybacking Holders
with respect to such offering), would materially adversely affect such offering, then the Company shall include in such Piggyback Underwritten Offering, to the extent of the total number of securities which the Company is so advised can be sold in
such offering without so materially adversely affecting such offering (the “Section 2.4 Maximum Number of Shares”), shares of Class A Common Stock in the following priority: 

(i)    First, (A) if the Piggyback Underwritten Offering is for the account of the Company, all shares of
Class A Common Stock that the Company proposes to include for its own account (the “Company Securities”) or, (B) if the Piggyback Underwritten Offering is for the account of any other Persons who have or have been granted
registration rights, all shares of Class A Common Stock that such Persons propose to include (the “Other Securities”); and 

(ii)    Second, (A) if the Piggyback Underwritten Offering is for the account of the Company, to the extent that the
number of Company Securities is less than the Section 2.4 Maximum Number of Shares, the shares of Class A Common Stock requested to be included by the Piggybacking Holders and holders of any other shares of Class A Common Stock
requested to be included by Persons having rights of registration on parity with the Piggybacking Holders with respect to such offering, pro rata among the Piggybacking Holders and such other holders based on the number of shares of
Class A Common Stock each requested to be included and, (B) if the Piggyback Underwritten Offering is for the account of any other Persons who have or have been granted registration rights, to the extent that the number of Other Securities
is less than the Section 2.4 Maximum Number of Shares, the shares of Class A Common Stock requested to be included by the Piggybacking Holders, pro rata among the Piggybacking Holders. 

  
 9 

 Section 2.5    Participation in
Underwritten Offerings. 
 (a)    In connection with any Underwritten Offering contemplated by
Section 2.2 or Section 2.4, the underwriting agreement into which each Selling Holder and the Company shall enter into shall contain such representations, covenants, indemnities (subject to
Article III) and other rights and obligations as are customary in Underwritten Offerings of securities by the Company. No Selling Holder shall be required to make any representations or warranties to or agreements with the Company or the
underwriters other than representations, warranties or agreements regarding such Selling Holder’s authority to enter into such underwriting agreement and to sell, and its ownership of, the securities being registered on its behalf, its intended
method of distribution and any other representation required by law. 
 (b)    Any participation by Holders in a
Piggyback Underwritten Offering shall be in accordance with the plan of distribution of the Company. 
 (c)    In
connection with any Piggyback Underwritten Offering in which any Holder has the right to include Registrable Securities pursuant to Section 2.4, such Holder agrees (A) to supply any information reasonably requested by
the Company in connection with the preparation of a Registration Statement and/or any other documents relating to such registered offering and (B) to execute and deliver any agreements and instruments being executed by all holders on
substantially the same terms reasonably requested by the Company or the Managing Underwriter, as applicable, to effectuate such registered offering, including, without limitation, underwriting agreements (subject to
Section 2.5(a)), custody agreements, lock-ups or “hold back” agreements pursuant to which such Holder agrees with the Managing Underwriter not to sell or purchase any
securities of the Company for the shorter of (i) the same period of time following the registered offering as is agreed to by the Company and the other participating holders (not to exceed the shortest number of days that a director of the
Company, “executive officer” (as defined under Section 16 of the Exchange Act) of the Company or any stockholder of the Company (other than a Holder or director or employee of, or consultant to, the Company) who owns 10% or more of
the outstanding Shares contractually agrees with the underwriters of such Piggyback Underwritten Offering not to sell any securities of the Company following such Piggyback Underwritten Offering and (ii) 60 days from the date of the execution of the
underwriting agreement with respect to such Piggyback Underwritten Offering), powers of attorney and questionnaires. 

Section 2.6    Registration Procedures. 

(a)    In connection with its obligations under this Article II, the Company will: 

(i)    promptly prepare and file with the Commission such amendments and supplements to such Registration Statement and
the prospectus used in connection therewith as may be necessary to keep such Registration Statement effective and to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such Registration
Statement until such time as all of such securities have been disposed of in accordance with the intended methods of disposition by the Selling Holder or Selling Holder thereof set forth in such Registration Statement; 

  
 10 

 (ii)    furnish to each Selling Holder such number of conformed copies
of such Registration Statement and of each such amendment and supplement thereto (in each case including without limitation all exhibits), such number of copies of the prospectus contained in such Registration Statement (including without limitation
each preliminary prospectus and any summary prospectus) and any other prospectus filed under Rule 424 under the Securities Act, in conformity with the requirements of the Securities Act, and such other documents, as such Selling Holder may
reasonably request; 
 (iii)    if applicable, use commercially reasonable efforts to register or qualify all
Registrable Securities and other securities covered by such Registration Statement under such other securities or blue sky laws of such jurisdictions as each Selling Holder thereof shall reasonably request, to keep such registration or qualification
in effect for so long as such Registration Statement remains in effect, and to take any other action which may be reasonably necessary or advisable to enable such Selling Holder to consummate the disposition in such jurisdictions of the securities
owned by such Selling Holder, except that the Company shall not for any such purpose be required to qualify generally to do business as a foreign corporation in any jurisdiction wherein it would not but for the requirements of this clause
(iii) be obligated to be so qualified or to consent to general service of process in any such jurisdiction; 

(iv)    in connection with an Underwritten Offering, use all commercially reasonable efforts to provide to each Selling
Holder a copy of any auditor “comfort” letters, customary legal opinions or reports of the independent petroleum engineers of the Company relating to the oil and gas reserves of the Company, in each case that have been provided to
the Managing Underwriter in connection with the Underwritten Offering; 
 (v)    promptly notify each Selling Holder,
at any time when a prospectus relating thereto is required to be delivered under the Securities Act, upon discovery that, or upon the happening of any event as a result of which, the prospectus included in such Registration Statement, as then in
effect, includes an untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances under which they were made, and at
the request of any such Selling Holder promptly prepare and file or furnish to such Selling Holder a reasonable number of copies of a supplement or post-effective amendment to the Registration Statement or a supplement to the related prospectus or
any document incorporated or deemed to be incorporated therein by reference, or file any other required document as may be necessary so that, as thereafter delivered to the purchasers of such securities, such prospectus shall not include an untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances under which they were made; 

(vi)    otherwise use its commercially reasonable efforts to comply with all applicable rules and regulations of the
Commission, and make available to its security holders, as soon as reasonably practicable, an earnings statement, which earnings statement shall satisfy the provisions of Section 11(a) of the Securities Act, and shall furnish to each such
Selling Holder at least the Business Day prior to the filing thereof a copy of any amendment or supplement to such Registration Statement or prospectus; 

  
 11 

 (vii)    provide and cause to be maintained a transfer agent and
registrar for all Registrable Securities covered by such Registration Statement from and after a date not later than the effective date of such Registration Statement; 

(viii)    cause all Registrable Securities covered by such Registration Statement to be listed on any securities exchange
on which the Class A Common Stock is then listed; and 
 (ix)    enter into such customary agreements and take
such other actions as the Holder or Holders shall reasonably request in order to expedite or facilitate the disposition of such Registrable Securities; and 

(x)    cause its officers to use their commercially reasonable efforts to support the marketing of the Registrable
Securities covered by the Registration Statement (including, without limitation, participation in electronic or telephonic “road shows”). 

(b)    Each Holder agrees by acquisition of such Registrable Securities that upon receipt of any notice from the Company
of the happening of any event of the kind described in Section 2.6(a)(v), such Holder will forthwith discontinue such Holder’s disposition of Registrable Securities pursuant to the Registration Statement until such
Holder’s receipt of the copies of the supplemented or amended prospectus contemplated by Section 2.6(a)(v) as filed with the Commission or until it is advised in writing by the Company that the use of such Registration
Statement may be resumed, and, if so directed by the Company, will deliver to the Company (at the Company’s expense) all copies, other than permanent file copies, then in such Holder’s possession of the prospectus relating to such
Registrable Securities current at the time of receipt of such notice. The Company may provide appropriate stop orders to enforce the provisions of this Section 2.6(b). 

Section 2.7    Cooperation by Holders. The Company shall have no obligation to
include Registrable Securities of a Holder in any Registration Statement or Underwritten Offering if such Holder has failed to timely furnish such information as the Company may, from time to time, reasonably request in writing regarding such Holder
and the distribution of such Registrable Securities that the Company determines, after consultation with its counsel, is reasonably required in order for any registration statement or prospectus supplement, as applicable, to comply with the
Securities Act. 
 Section 2.8    Restrictions on Public Sale by Holders;
Lockups. Each Holder agrees not to effect any public sale or distribution of Registrable Securities for a period of up to 30 days following completion of an Underwritten Offering of equity securities by the Company; provided that
(i) the Company gives written notice to such Holder of the date of the commencement and termination of such period with respect to any such Underwritten Offering and (ii) the duration of the foregoing restrictions shall be no longer than
the duration of the shortest restriction generally imposed by the underwriters of such public sale or distribution on the Company or on the officers or directors or any other shareholder of the Company on whom a restriction is imposed; provided
further, that this Section 2.8 shall not apply to any Holder that, (i) together with such Holder’s Affiliates, holds less than 5% of the Company’s outstanding Class A Common Stock or (ii) has
delivered (and not revoked) an Opt-Out Notice to the Company. 

  
 12 

 Section 2.9    Expenses. The
Company shall be responsible for all Registration Expenses incident to its performance of or compliance with its obligations under this Article II. Each Selling Holder shall pay its pro rata share of all Selling Expenses in connection with
any sale of its Registrable Securities hereunder. 
 Section 2.10    Other Registration
Rights. From and after the date hereof, the Company shall not, without the prior written consent of the Majority Holders, enter into or amend any agreement with any current or future holder of any securities of the Company that would allow
such current or future holder to require the Company to include securities in any registration statement filed by the Company for such Holders on a basis other than expressly subordinate to, the piggyback rights of the Holders hereunder;
provided, that in no event shall the Company enter into any agreement that would permit another holder of securities of the Company to participate on a pari passu basis (in terms of priority of cut-back based on advice of underwriters) with a Requesting Holder in a Shelf Underwritten Offering. The Holders acknowledge that the piggyback rights with respect to shares of Class A Common Stock granted to
certain persons pursuant to (a) the Second Amended and Restated Registration Rights Agreement dated April 20, 2017, by and among the Company, Parsley Energy, LLC and the Owners (as defined therein) and (b) the Registration Rights and Lock-Up Agreement dated April 20, 2017 (the “DE Registration Rights Agreement”), by and among the Company and the holders party thereto (each as may be amended or supplemented from time to time)
shall, subject to Section 2.10 of the DE Registration Rights Agreement, rank pari passu with the piggyback rights of the Holders hereunder. 

ARTICLE III 

INDEMNIFICATION AND CONTRIBUTION 

Section 3.1    Indemnification by the Company. The Company will indemnify and hold
harmless each Selling Holder, its officers and directors and each Person (if any) that controls such Holder within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act from and against any and all
losses, claims, damages, liabilities, costs (including costs of preparation and attorneys’ fees and any legal or other fees or expenses incurred by such Person in connection with any investigation or Proceeding), expenses, judgments, fines,
penalties, charges and amounts paid in settlement (“Losses”) as incurred, caused by, arising out of or based upon, resulting from or related to any untrue statement or alleged untrue statement of a material fact contained in any
Registration Statement or prospectus relating to the Registrable Securities (as amended or supplemented if the Company shall have furnished any amendments or supplements thereto) or any preliminary prospectus, any filing made in connection with the
qualifications of the offering under the securities or other Blue Sky laws of any jurisdiction in which Registrable Securities are offered, or any other offering document (including any related notification, or the like) incident to any such
registration, qualification, or compliance, or based on any or any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading (in the case of any prospectus,
in the light of the circumstances under which such statement is made), or any violation by the Company of this Agreement, the Securities Act or the Exchange Act, or any rule or regulation thereunder applicable to the Company and relating to action
or inaction required of the Company in connection with any such registration, qualification, or compliance, provided, however, that such indemnity shall not apply to that portion of such Losses caused by, or arising out of, any untrue
statement, or alleged untrue statement or any such omission or alleged omission, to the extent such statement or omission was made in reliance upon and in conformity with information furnished in writing to the Company by or on behalf of such Holder
expressly for use therein. 

  
 13 

 Section 3.2    Indemnification by the
Holders. Each Holder agrees to indemnify and hold harmless the Company, its officers and directors and each Person (if any) that controls the Company within the meaning of either Section 15 of the Securities Act or Section 20 of
the Exchange Act from and against any and all Losses caused by, arising out of, resulting from or related to any untrue statement or alleged untrue statement of a material fact contained in any Registration Statement or prospectus relating to
Registrable Securities (as amended or supplemented if the Company shall have furnished any amendments or supplements thereto) or any preliminary prospectus, or any omission or alleged omission to state therein a material fact required to be stated
therein or necessary to make the statements therein not misleading (in the case of any prospectus, in the light of the circumstances under which such statement is made), only to the extent such statement or omission was made in reliance upon and in
conformity with information furnished in writing by or on behalf of such Holder expressly for use in any Registration Statement or prospectus relating to the Registrable Securities, or any amendment or supplement thereto, or any preliminary
prospectus. 
 Section 3.3    Indemnification Procedures. In case any Proceeding
(including any governmental investigation) shall be instituted involving any Person in respect of which indemnity may be sought pursuant to Section 3.1 or Section 3.2, such Person (the
“Indemnified Party”) shall promptly notify the Person against whom such indemnity may be sought (the “Indemnifying Party”) in writing (provided that the failure of the Indemnified Party to give notice as provided
herein shall not relieve the Indemnifying Party of its obligations under this Article III, except to the extent the Indemnifying Party is actually prejudiced by such failure to give notice), and the Indemnifying Party shall be entitled to
participate in such Proceeding and, unless in the reasonable opinion of outside counsel to the Indemnified Party a conflict of interest between the Indemnified Party and Indemnifying Party may exist in respect of such claim, to assume the defense
thereof jointly with any other Indemnifying Party similarly notified, to the extent that it chooses, with counsel reasonably satisfactory to such Indemnified Party, and after notice from the Indemnifying Party to such Indemnified Party that it so
chooses, the Indemnifying Party shall not be liable to such Indemnified Party for any legal or other expenses subsequently incurred by such Indemnified Party in connection with the defense thereof other than reasonable costs of investigation;
provided, however, that (i) if the Indemnifying Party fails to assume the defense or employ counsel reasonably satisfactory to the Indemnified Party, (ii) if such Indemnified Party who is a defendant in any action or
Proceeding which is also brought against the Indemnifying Party reasonably shall have concluded that there may be one or more legal defenses available to such Indemnified Party which are not available to the Indemnifying Party or (iii) if
representation of both parties by the same counsel is otherwise inappropriate under applicable standards of professional conduct then, in any such case, the Indemnified Party shall have the right to assume or continue its own defense as set forth
above (but with no more than one firm of counsel for all Indemnified Parties in each jurisdiction, except to the extent any Indemnified Party or Parties reasonably shall have concluded that there may be legal defenses available to such party or
parties which are not available to the other Indemnified Parties or to the extent representation of all Indemnified Parties by the same counsel is otherwise inappropriate under applicable standards of professional conduct) and the Indemnifying Party
shall be liable for any expenses therefor. No Indemnifying Party shall, without the written consent of the Indemnified Party, effect the settlement or compromise of, or consent to 

  
 14 

 
the entry of any judgment with respect to, any pending or threatened action or claim in respect of which indemnification or contribution may be sought hereunder (whether or not the Indemnified
Party is an actual or potential party to such action or claim) unless such settlement, compromise or judgment (A) includes an unconditional release of the Indemnified Party from all liability arising out of such action or claim and
(B) does not include a statement as to, or an admission of, fault, culpability or a failure to act, by or on behalf of any Indemnified Party. 

Section 3.4    Contribution. 

(a)    If the indemnification provided for in this Article III is unavailable to an Indemnified Party in respect of
any Losses in respect of which indemnity is to be provided hereunder, then each Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall to the fullest extent permitted by law contribute to the amount paid or payable by such
Indemnified Party as a result of such Losses in such proportion as is appropriate to reflect the relative fault of such party in connection with the statements or omissions that resulted in such Losses, as well as any other relevant equitable
considerations. The relative fault of the Company (on the one hand) and a Holder (on the other hand) shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or
alleged omission to state a material fact relates to information supplied by such party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. 

(b)    The Company and each Holder agree that it would not be just and equitable if contribution pursuant to this
Article III were determined by pro rata allocation or by any other method of allocation that does not take account of the equitable considerations referred to in Section 3.4(a). The amount paid or payable by an
Indemnified Party as a result of the losses, claims, damages or liabilities referred to in Section 3.4(a) shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably
incurred by such Indemnified Party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this Article III, no Holder shall be liable for indemnification or contribution pursuant to this
Article III for any amount in excess of the net proceeds of the offering received by such Holder, less the amount of any damages which such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or
omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent
misrepresentation. 
 ARTICLE IV 

RULE 144 
 With a view to
making available the benefits of certain rules and regulations of the Commission that may permit the resale of the Registrable Securities without registration, the Company agrees to use its commercially reasonable efforts to: 

(a)    make and keep public information regarding the Company available, as those terms are understood and defined in Rule
144 under the Securities Act, at all times from and after the date hereof; 

  
 15 

 (b)    file with the Commission in a timely manner all reports and other
documents required of the Company under the Securities Act and the Exchange Act at all times from and after the date hereof; and 

(c)    so long as a Holder owns any Registrable Securities, furnish (i) to the extent accurate, forthwith upon
request, a written statement of the Company that it has complied with the reporting requirements of Rule 144 under the Securities Act and (ii) unless otherwise available via the Commission’s EDGAR filing system, to such Holder forthwith
upon request a copy of the most recent annual or quarterly report of the Company, and such other reports and documents so filed as such Holder may reasonably request in availing itself of any rule or regulation of the Commission allowing such Holder
to sell any such securities without registration. 
 ARTICLE V 

TRANSFER OR ASSIGNMENT OF REGISTRATION RIGHTS 

The rights to cause the Company to register Registrable Securities under Article II of this Agreement may be
transferred or assigned by each Holder to one or more Transferees or assignees of Registrable Securities if such Transferee is a Permitted Transferee and such Transferee has delivered to the Company a duly executed Adoption Agreement. 

ARTICLE VI 

MISCELLANEOUS 

Section 6.1    Effectiveness. This Agreement shall not become effective until the
Effective Time and shall thereafter be effective until terminated in accordance with the terms of this Agreement. In the event that the Merger Agreement is terminated prior to the consummation of the transactions contemplated thereby, this Agreement
and all the terms hereunder shall also terminate, regardless of any other provisions set forth in this Agreement. 

Section 6.2    Termination. After effectiveness in accordance with
Section 6.1, this Agreement shall terminate, and the parties shall have no further rights or obligations hereunder on (a) the tenth anniversary of the date hereof or (b) as to any Holder, on such earlier date on which both
(i) such Holder, together with such Holder’s Affiliates, owns less than 2.5% of the Company’s voting securities and (ii) all Registrable Securities owned by such Holder and such Holder’s Affiliates may be sold without
restriction (including any limitation thereunder on volume or manner of sale and without the need for current public information) pursuant to Rule 144 under the Securities Act; provided, however, that Article III shall
survive any termination hereof. 
 Section 6.3    Severability. If any provision
of this Agreement shall be determined to be illegal and unenforceable by any court of law, the remaining provisions shall be severable and enforceable in accordance with their terms. 

Section 6.4    Governing Law; Waiver of Jury Trial. 

(a)    This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without
regard to principles of conflicts of laws that would direct the application of the laws of another jurisdiction. 

  
 16 

 (b)    THE PARTIES HEREBY WAIVE TRIAL BY JURY IN ANY ACTION, PROCEEDING
OR COUNTERCLAIM BROUGHT BY ANY PARTY AGAINST ANOTHER IN ANY MATTER WHATSOEVER ARISING OUT OF OR IN RELATION TO OR IN CONNECTION WITH THIS AGREEMENT. FURTHER, NOTHING HEREIN SHALL DIVEST A COURT OF COMPETENT JURISDICTION OF THE RIGHT AND POWER TO
GRANT A TEMPORARY RESTRAINING ORDER, TO GRANT TEMPORARY INJUNCTIVE RELIEF, OR TO COMPEL SPECIFIC PERFORMANCE OF ANY DECISION OF AN ARBITRAL TRIBUNAL MADE PURSUANT TO THIS PROVISION. 

Section 6.5    Adjustments Affecting Registrable Securities. The provisions of
this Agreement shall apply to any and all shares of capital stock of the Company or any successor or assignee of the Company (whether by merger, consolidation, sale of assets or otherwise) which may be issued in respect of, in exchange for or in
substitution for the Class A Shares, by reason of any stock dividend, split, reverse split, combination, recapitalization, reclassification, merger, consolidation or otherwise in such a manner and with such appropriate adjustments as to reflect
the intent and meaning of the provisions hereof and so that the rights, privileges, duties and obligations hereunder shall continue with respect to the capital stock of the Company as so changed. 

Section 6.6    Binding Effects; Benefits of Agreement. This Agreement shall be
binding upon and inure to the benefit of the Company and its successors and assigns and each Holder and its successors and assigns. Except as provided in Article V, neither this Agreement nor any of the rights, benefits or obligations
hereunder may be assigned or transferred, by operation of law or otherwise, by any Holder without the prior written consent of the Company. 

Section 6.7    Notices. All notices or other communications which are required or
permitted hereunder shall be in writing and shall be deemed to have been given if (i) personally delivered or sent by telecopier, (ii) sent by nationally recognized overnight courier (iii) sent by registered or certified mail, postage
prepaid, return receipt requested or (iv) email, addressed as follows: 
 (a)    If to the Company, to: 

Parsley Energy, Inc. 
 303
Colorado Street, Suite 3000 
 Austin, Texas 78701Attention: General Counsel 

Email: CRoberts@parsleyenergy.com 

(b)    If to an Initial Holder, to the address of the Initial Holder as it appears on the Initial Holder’s signature
page attached hereto or such other address as may be designated in writing by the Initial Holder; and 
 (c)    If to
any other Holders, to their respective addresses set forth on the applicable Adoption Agreement; 
 or to such other address as the party to whom notice is
to be given may have furnished to such other party in writing in accordance herewith. Any such communication shall be deemed to have been received (a) when delivered, if personally delivered or sent by telecopier, (b) the next

  
 17 

 
Business Day after delivery, if sent by nationally recognized, overnight courier(c) on the third (3rd) Business Day following the date on which the piece of mail containing such communication is
posted, if sent by first-class mail and (d) upon actual receipt of the email, if sent via email. 

Section 6.8    Modification; Waiver. This Agreement may be amended, modified or
supplemented only by a written instrument duly executed by the Company and the Majority Holders. No course of dealing between the Company and the Holders (or any of them) or any delay in exercising any rights hereunder will operate as a waiver of
any rights of any party to this Agreement. The failure of any party to enforce any of the provisions of this Agreement will in no way be construed as a waiver of such provisions and will not affect the right of such party thereafter to enforce each
and every provision of this Agreement in accordance with its terms. 

Section 6.9    Entire Agreement. Except as otherwise expressly provided herein,
this Agreement constitutes the entire agreement among the parties pertaining to the subject matter hereof and supersedes all prior and contemporaneous agreements and understandings of the parties in connection therewith. 

Section 6.10    Counterparts. This Agreement may be executed in any number of
counterparts, and each such counterpart shall be deemed to be an original instrument, but all such counterparts taken together shall constitute but one agreement. 

[signature page follows] 

  
 18 

 IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be executed by its
undersigned duly authorized representative as of the date first written above. 
  

			
	PARSLEY ENERGY, INC.
		
	By:	 	 /s/ Matt Gallagher

	Name:	 	Matt Gallagher
	Title:	 	President and Chief Executive Officer

 SIGNATURE PAGE TO REGISTRATION
RIGHTS AGREEMENT 

 
					
	 Q-JAGGED PEAK ENERGY INVESTMENT PARTNERS, LLC

			
		 	By:	 	 /s/ James V. Baird

		 	Name:	 	James V. Baird
		 	Title:	 	Authorized Person
		
		 	Address:
			
		 		 	Prior to November 1, 2019:
			
		 		 	1401 McKinney St, Suite 2700
		 		 	Houston, TX 77010
			
		 		 	After October 31, 2019:
			
		 		 	800 Capitol St, Suite 3600
		 		 	Houston, TX 77002
		
		 	Contact Person: General Counsel
		 	Telephone No: 713-452-2020
		 	Email: GeneralCounsel@quantumep.com

 SIGNATURE PAGE TO REGISTRATION
RIGHTS AGREEMENT 

 EXHIBIT A 

ADOPTION AGREEMENT 
 This
Adoption Agreement (“Adoption Agreement”) is executed by the undersigned transferee (“Transferee”) pursuant to the terms of the Registration Rights Agreement, dated as of October 14, between Parsley Energy,
Inc. (the “Company”) and the Holders party thereto (as amended from time to time, the “Registration Rights Agreement”). Terms used and not otherwise defined in this Adoption Agreement have the meanings set forth in
the Registration Rights Agreement. 
 By the execution of this Adoption Agreement, the Transferee agrees as follows: 

 

	1.	 Acknowledgement. Transferee acknowledges that Transferee is acquiring certain shares of Class A
Common Stock of the Company, subject to the terms and conditions of Registration Rights Agreement, among the Company and the Holders party thereto. 

  

	2.	 Agreement. Transferee (i) agrees that the shares of Class A Common Stock of the Company
acquired by Transferee shall be bound by and subject to the terms of the Registration Rights Agreement, pursuant to the terms thereof, and (ii) hereby adopts the Registration Rights Agreement with the same force and effect as if he, she or it
were originally a party thereto. 

  

	3.	 Notice. Any notice required as permitted by the Registration Rights Agreement shall be given to
Transferee at the address listed beside Transferee’s signature below. 

  

	4.	 Joinder. The spouse of the undersigned Transferee, if applicable, executes this Adoption Agreement to
acknowledge its fairness and that it is in such spouse’s best interest, and to bind such spouse’s community interest, if any, in the shares of Class A Common Stock and other securities referred to above and in the Registration Rights
Agreement, to the terms of the Registration Rights Agreement. 

  

	
	Signature:
	
	  

	  

	
	Address:
	Contact Person:
	Telephone No:
	Email:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]